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CHAPTER I  
STATEMENT OF THE PROBLEM 
 
Advancements in medicine and better lifestyles have increased the human life 
expectancy in the past century[1]. Women in particular are living longer than men, about 
5 years more (81 vs 76 years respectively in the United States). The shift in life 
expectancy has resulted in women living a third of their lives with very low levels of 
circulating estrogens due to the onset of menopause remaining constant over the same 
time period. Longer lifespans have also resulted in an increase in age related disorders, 
especially cognitive disorders such as Alzheimer’s, dementia, and mood disorders. 
Disorders of the brain present an enormous personal and financial cost to individuals and 
their families.  
Estradiol (17β-estradiol, E2) is the major circulated sex steroid hormone in 
women, and it has been shown to have many beneficial physiological effects especially in 
the brain. It is suggested that E2 is the reason that women have significantly decreased 
risks for acquiring cognitive diseases. However the beneficial effect of E2 is lost after 
menopause, a period of time in a women’s life when their circulating E2 levels decline. 
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The declining levels of E2 are correlated with an increased risk for cardiovascular 
disease, osteoporosis, and cognitive decline.  
Hormone Therapy (HT) is used to increase the E2 levels in women who are going 
through the menopausal transition to alleviate the negative symptoms associated with 
menopause and decrease the risk of chronic diseases. Clinical and basic science research 
had previously shown that HT provided protection from cognitive decline and reduced 
the risk of dementia [2,3,4]. However the evidence was far from concrete and therefore 
the Women’s Health Initiative (WHI) clinical trial was designed to study the safety and 
effectiveness of HT. The results of the WHI demonstrated that HT had no beneficial 
effects for cognitive decline and, in some cases, increased the risk of dementia in post-
menopausal women. The findings of the WHI convinced many physicians to stop 
prescribing HT to their patients and caused a lot concern among patients. However, 
further analysis of WHI data showed that when HT was given to women who were just 
starting menopause, they experienced beneficial effects including a decreased risk for 
cognitive decline and a reduced risk of dementia. The results suggested that there was a 
“critical window” for the treatment of menopausal women, past which HT would not be 
effective. 
Hormone therapy is still a controversial treatment and is currently not widely 
used. However, the developments of alternative therapies or recommendations for the use 
of HT are notably lacking. The insufficient progress is the result of a paucity of 
knowledge of E2 molecular actions in the brain and how they are altered with aging.  
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Estradiol is known to regulate the transcription of genes through its nuclear receptors the 
estrogen receptors. However the new millennium brought forth a new mechanism for the 
regulation of gene expression: a group of small regulatory non-coding RNAs called 
microRNAs (miRNAs). miRNAs regulate a myriad of cellular processes by repressing 
the translation of protein-coding genes. Recent studies have demonstrated that miRNAs 
are critical regulators of brain development and function. Just like any gene, the 
expressions of miRNAs are modulated by many different extracellular signals, including 
E2. However the vast majority of studies of E2 regulation of miRNAs have only been in 
performed using cancer tumors or cell lines as a model system, there has been no research 
to date addressing how aging might alter that regulation.  
Hypothesis 
In the present study, I hypothesized that estrogen, specifically 17β-estradiol, differentially 
regulates mature miRNA expression in the brain with advanced aging resulting in 
decreased expression levels target genes. To test this hypothesis, I developed three 
specific aims: 
Specific Aims 
1. Define the factors responsible for the critical window of time for altered E2 
regulation of miRNA expression in the brain. The "Timing Hypothesis" suggests that E2 
replacement therapy has positive effects on neurological function, but only within a 
restricted period of time. We hypothesize that this is partially due to the age dependent 
differential effects of E2-mediated miRNA expression patterns we observed in female 
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rats. This aim will determine whether aging or increased lengths of E2 deprivation are 
responsible for the alterations in miRNA expression. Chapters III and IV will explore this 
aim.  
2. Elucidate the precise ER subtype mediating E2-mediated miRNA expression. The 
two ER subtypes have different regional distributions and functions in the brain. For 
example, ERβ has been shown to be a positive regulator of mood and antagonize the 
actions of ERα. This aim will determine the precise ER mediating the effects of E2 on 
miRNAs and determine the mechanism of E2 of miRNA expression. Chapters IV and VI 
will explore this aim. 
3. Identify the gene targets of E2 regulated miRNAs in the brain. Ultimately, the 
functional significance of these changes in miRNA expression is dependent on the 
specific mRNA targets of the miRNA. This aim will use bioinformatic analysis to 
identify the target genes for the miRNAs regulated by E2. Chapter III will explore this 
aim. 
Impact 
Knowledge of the molecular actions of estrogen in the brain is required to develop novel 
therapies for post-menopausal women and provide a foundation for understanding the 
clinical results of hormone therapy. The results of this dissertation provide evidence of 
the direct regulation of miRNAs by E2 in the brain and identify a set of miRNAs that are 
regulated in an age-dependent manner. These data suggest that miRNAs could be a 
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mechanistic explanation for the observed altered efficacy of HT in post-menopausal 
women 
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CHAPTER II  
REVIEW OF THE LITERATURE 
 
Menopause 
Menopause is the termination of the menstrual cycle and thereby marks the end of the 
reproductive years for a woman. The average age of menopause is about 51 years of age 
and is preceded by the loss of ovarian follicles which results in decreased production of 
17β-estradiol (estradiol, E2), the major circulating estrogen in women. The increase in 
life expectancy has resulted in women living more than half their lives without 
circulating E2, thereby increasing their risk of developing these chronic cognitive 
disorders. The loss of circulating E2 is considered to be a major contributing factor for 
increased risk of chronic diseases such as osteoporosis, cardiovascular diseases, and 
cognitive disorders in post-menopausal women.  
Estradiol is a known regulator of many neurobiological processes including memory and 
mood. Post-menopausal women are at increased risk for developing mild cognitive 
impairment, dementia, and Alzheimer’s disease (AD) [4], all of which affect learning and 
memory processes. Additionally, post-menopausal women are at increased risk for 
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developing mood disorders such major depressive disorder (MDD) [5,6,7], and women 
with MDD have also been shown to have low circulating levels of E2[8]. Conversely, 
women with high circulating levels of E2 have been shown to have a blunted activation 
of brain regions associated with the stress response when given a stress challenge, which 
would result in a decreased risk for acquiring a mood disorder [9].   
  
Hormone Therapy 
The treatment of post-menopausal women to prevent these chronic cognitive disorders is 
through use of hormone therapy (HT), the goal of which is to increase the circulating E2 
levels. The HT used in the United States is a conjugated equine estrogen (CEE) sold 
under the brand name Premarin, which is a 50:50 combination of estrone (another type of 
estrogen) and E2. CEE is also given in conjunction with synthetic progesterone, 
medroxyprogesterone acetate (MPA), to women who still have an intact uterus (i.e. have 
not had prior hysterectomy) to prevent endometrial cancer.   
Small clinical trials initially supported the idea of increased E2 levels providing 
beneficial outcomes in post-menopausal women.  For instance, the risk of dementia was 
decreased with HT and women reported less depressive symptoms while receiving HT 
[10,11]. Basic science studies using animal models also supported the use of HT. 
Estradiol treatment has been shown to be neuro-protective in animals following an 
experimentally-induced stroke [12]. Further, removal of endogenous circulating E2 by 
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ovariectomy in animal models resulted in decreased performance on learning and 
memory tasks, and the deficits in performance were rescued by E2 treatment [13]. 
Finally, depressive behaviors were decreased in rats given E2 treatment [14]. While there 
was mounting evidence for the benefits of HT, there were also studies that showed no 
beneficial effect of HT in postmenopausal women [15].  In addition, there was not much 
known about the possible health risks associated with women taking HT. Therefore a 
larger study was needed to settle the question of the effectiveness and safety of HT.  
The Women’s Health Initiative (WHI) 
The Women’s Health Initiative (WHI) was the first ever large scale clinical trial to test 
the safety and effectiveness of HT for the purpose of preventing chronic disease. In the 
U.S. about 40% of women were using HT before WHI findings were published publicly. 
The trial enrolled 27,347 post-menopausal women, with an age range between 50-79 
years old, between 1993 and 1998. Women that had not undergone prior hysterectomy 
(i.e. uterus intact; N =16,608) were given oral CEE (0.625 mg/d) with MPA (2.5 mg/d), 
while another group of 10,739 women with a prior hysterectomy were given CEE alone 
[16]. The women were followed throughout their treatment and assessed periodically. 
The results shocked the clinical and basic science communities. Contrary to previous data 
the WHI studies revealed that HT was in fact detrimental to postmenopausal women’s 
health [16]. A sub-study of the WHI, the Women’s Health Initiative Memory Study 
(WHIMS), showed that HT actually increased the risk for mild cognitive impairment 
(MCI) and dementia [5,6,7].  The WHIMS study also showed a significant association 
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between MCI, dementia, and depressive symptoms [5,7]. Overall the WHI studies 
concluded that HT was not appropriate treatment for chronic cognitive disorders in post-
menopausal women. The results caused the physicians across the nation to reject 
hormone therapy.   
The Timing Hypothesis 
The overall conclusion of the WHI data seemed to indicate that HT was not an effective 
treatment. However, detailed analysis of the data revealed that there was a time gap in the 
effectiveness of HT. Women who received HT just as they were starting the progression 
of menopause showed a decreased risk for AD, however women who initiated HT 10 
years post-menopause had an increased risk for AD [4]. Other studies have also 
demonstrated that the early administration of HT reduced the risk of developing MCI [2]. 
Collectively the findings indicated that there is a “critical window” for HT to be 
effective. As of this writing there are two clinical trials, ELITE (Early versus Late 
Intervention Trail with Estradiol) and KEEPS (Kronos Early Estrogen Prevention Study), 
currently in progress, which are aimed at specifically testing the “Timing Hypothesis”. 
Importantly both of these studies will also test the efficacy of synthetic bioidentical 
human E2 compared to CEE [17]. One of main criticisms of the WHI study was the use 
of CEE because it was not a chemically pure E2, which might have contributed to the 
lack of effectiveness.  
The Timing Hypothesis raises the possibility that there is an alteration in the molecular 
mechanisms that mediate HT effects on cognition during the period when a woman has 
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low circulating E2 levels. In animal models there has been some evidence for a “critical 
window” for estrogen effects on memory [18,19]. However, currently there is no 
molecular mechanism described to account for the “Timing Hypothesis”. Estradiol 
primarily regulates the transcription of genes through the ligand activated transcription 
factor the estrogen receptor. There are two isoforms of the estrogen receptor, ERα and 
ERβ, both of which have distinct expression patterns in the brain. Aging results in the 
altered expression of estradiol responsive genes in brain, however it is not known what is 
causing the change. Both of these receptors have been shown to be decreased in 
expression with aging in animal models, however it is brain region dependent and not 
consistent. In the early 2000’s a group of non-coding RNAs called microRNAs 
(miRNAs) came to prominence. These small RNAs were shown to have a powerful 
regulatory role in the biological processes by repressing gene expression at the post-
transcriptional level. miRNAs were quickly shown to be regulated by estradiol in cancers, 
however  no published data had explored if estradiol could regulate miRNA expression in 
the brain. 
MicroRNAs 
Documented evidence through most of the twentieth century showed that RNA played a 
passive role in the flow of genetic information. However, in the 1980s evidence emerged 
that RNAs consisting of fewer than 100 nucleotides could regulate the translation of 
genes in E. coli [20]. This was followed by work from Victor Ambros and David Ruvkun 
demonstrating that small RNAs were responsible for regulating key developmental steps 
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in C. elegans [21,22]. However, no mechanism had been ascribed to these small RNAs, 
until Craig Mello and Andrew Fire demonstrated that short RNA duplexes could induce 
the degradation of a complementary messenger (m)RNA at the post-transcriptional level, 
a mechanism that was soon named RNA interference (RNAi) [23,24,25]. 
Mello and Fire’s seminal manuscript was soon followed by the discovery of endogenous 
small RNAs with RNAi capabilities; these small RNAs were named microRNAs 
(miRNAs) [26,27,28,29]. miRNAs had been described in lower organisms such as C. 
elegans and drosophila, yet it was immediately noticed that these small RNA sequences 
were evolutionary conserved with other higher organisms such as humans [27,28,29]. It 
wasn’t long before miRNAs were being profiled with deep sequencing experiments in a 
variety of mammals including rodents, non-human primates, and humans. As of this 
writing there are 2588 and 765 identified miRNA sequences in human and rat genomes, 
respectively (miRBase 21) [30].  
miRNAs are encoded from either intergenic (between protein coding sequences) or 
intragenic (lying within the intron of protein coding genes) regions of the genome 
[31,32,33,34,35,36,37]. The majority of miRNAs are dependent on RNA polymerase II 
for their transcription, however there are about third of miRNAs that may be RNA 
polymerase III dependent [35,36,37]. RNA pol III dependent miRNAs lie within ALU 
repeat elements in the DNA [36]. Genome-wide association studies have shown that 
intergenic miRNAs have similar core promoter elements as protein coding genes 
[35,38,39,40,41]. The core promoters of these small RNAs lie within ~500bp of the 
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miRNA sequence and contain TATA box motifs along with CpG islands [35,41]. 
Transcription factor binding motifs are also abundant amongst the majority of intergenic 
miRNAs [40]. Intragenic or intronic (also known as mirtrons) miRNAs make up a small 
percentage of miRNA sequences in mammals, but are highly abundant in lower 
organisms [35,38,42]. Mirtrons were thought to be dependent on the promoter of the gene 
they lie within, however there is recent evidence that they have their own promoters from 
which they can be independently transcribed [38,42]. Taken together the experimental 
evidence has demonstrated that miRNAs are under the same complex regulatory 
mechanisms that control protein-coding genes. Additionally, miRNAs are also subjected 
to extensive posttranscriptional enzymatic processing before they become a function unit 
in the cell. 
MicroRNA Biogenesis 
The transcription of a miRNA gene leads to the production of a long RNA transcript 
termed a primary miRNA (pri-miRNA; Fig. 1) [32,43,44]. This pri-miRNA transcript 
contains hairpin secondary structures, which is where the mature miRNA resides. The 
hairpin structure is cleaved from the pri-miRNA, the freed hairpin RNA is then called a 
precursor miRNA (pre-miRNA). The cleavage event that converts the pri-miRNA to the 
pre-miRNA is catalyzed by the RNase III enzyme drosha [45]. Importantly, RNase III 
enzymes can only cleave double stranded RNA molecules. Drosha is accompanied by the 
RNA binding protein DGCR8 (di-George syndrome critical region 8), and together they 
form the microprocessor complex [46,47]. Drosha is capable of cleaving the pri-miRNA 
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to pre-miRNA without DGCR8, or other accessory proteins; however the efficiency of 
the reaction is very low [46]. DGCR8 binds to the hairpin RNA and acts as a “molecular 
ruler” for drosha, so that the RNase III enzyme can cleave at the correct 5’ and 3’ ends of 
the hairpin [46]. The cleavage event results in the 3’ end that is two bases longer than the 
5’ end.  
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Figure 1. MicroRNA biogenesis pathway. 
The figure is modified from Kim VN, Nature Reviews Molecular Cell Biology. 2005. 
TRB
P 
AGO2 
POL II/III 
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There is some evidence that cleavage of the pri-miRNA to pre-miRNA is a co-
transcriptional event [32,44]. For instance, Drosha and DGCR8 have been co-
immunoprecipitated with RNA pol II, demonstrating co-transcriptional occupancy, and 
transcriptional inhibition using actinomycin D halts microprocessor activity [32].  
The resulting pre-miRNA is then exported out of the nucleus and into the cytoplasm via 
the double-stranded RNA binding protein, exportin-5 [48,49]. Once in the cytoplasm, the 
pre-miRNA is then cleaved by another RNase III enzyme, dicer. Dicer cleaves the hairpin 
pre-miRNA to form a RNA duplex [50,51]. Dicer forms a herterodimeric complex with 
another RNA binding protein, Tar RNA binding protein (TRBP), which regulates the 
activity of dicer [52,53,54]. Unlike drosha, dicer can efficiently cleave RNAs without its 
binding partners. Notably, mirtrons are the exception to this paradigm, in that they do not 
require the microprocessor complex for pre-miRNA formation. Instead, the pre-miRNA 
is cleaved as a result of intron splicing components, similar to what occurs with the 
processing for other types of RNAs [33]. 
 Once the miRNA duplex has been formed, the leading strand (also called the 
Guide) is selected for use in targeting mRNAs, while the lagging strand (LAO called the 
Passenger) is typically degraded [55]. However, this is not always the case. For example, 
the lagging strand has been shown to repress mRNAs as well, which suggests that a 
miRNA duplex could have dual roles with each strand repressing distinct mRNA pools 
[55,56,57,58].  The mature 22 nucleotide miRNA is then loaded on to an agronaute 
protein for mRNA targeting. The argonaute proteins form the core of the RNA-induced-
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silencing complex (RISC), which constitutes a multimetric protein complex responsible 
for binding to mRNA and repressing mRNA translation [59,60,61]. There are multiple 
argonaute proteins that associate with miRNAs. In humans, there are four currently 
identified argonaute proteins (AGO1, AGO2, AGO3, and AGO4), with AGO2 being the 
only one that can cleave mRNAs [62]. AGO2 also been shown to be important for the 
processing of the pre-miRNA to the RNA duplex by associating with dicer [52]. 
However, there has been a description of an RNase III independent biogenesis of 
miRNAs, where pre-miRNA cleavage is accomplished by the actions of AGO2 [63].  
MicroRNA Regulation of Gene Expression 
miRNAs associated with the RISC complex bind to a complementary sequence on the 3’ 
untranslated region (UTR) of a mRNA to repress the translation and/or degrade the 
mRNA transcript [64]. The first 2-8 nucleotides on the 5’ end of the miRNA, termed the 
seed sequence, determine the specificity of binding to a particular mRNA sequence [64]. 
Unlike in plants, animal miRNAs do not share perfect complimentary binding with their 
target mRNA sequences. Thus, this loose base pairing makes miRNAs highly 
promiscuous in their ability to regulate multiple target mRNAs. Indeed, experimental 
evidence has shown that overexpression of a single miRNA can result in the repression of 
hundreds of genes [61,64]. Based on sequence complementarily, miRNAs could 
potentially bind to sites other than the 3’UTR of the target mRNA. Specifically, miRNA 
binding to the coding region of an mRNA transcript has also been shown to repress 
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translation [70]. These data suggest that translational repression and degradation can be 
predicted based on the location of miRNA binding to the mRNA transcript.  
Translational repression has been shown to precede mRNA degradation by recruiting 
eIF6 to inhibit the 80s ribosomal subunit assembly, thereby preventing 43s ribosomal 
scanning of the mRNA transcript [65,66,67,68]. Once translation has been stalled, the 
RISC complex recruits the Carbon Catabolite Repressor protein 4-Negative On TATA 
(CCR4-NOT) de-adenylation complex to remove the poly-A tail of the mRNA, which 
signals exoribonulcease-mediated degradation [69]. The effect of miRNAs on protein 
expression has been shown to be modest, which is likely due to the many other regulatory 
factors that can impact a particular protein [70,71,72]. Therefore, it is hypothesized that 
the main role for miRNAs is to “fine tune” protein expression; a subtle change that may 
be necessary to maintain homeostasis in the face of changing cellular conditions [71]. 
However, there are instances where miRNAs can act as switches of protein expression. 
Mukherji and colleagues demonstrated that miRNAs could act as both a switch (i.e. 
on/off) and fine tuner, with the mRNA expression being the dependent variable [70]. For 
example, they showed that a particular miRNA was highly repressive when the target 
mRNA expression was below a certain threshold, however as the mRNA expression 
reached threshold, the miRNA would only modestly repress the expression, thereby 
acting to “fine tune” protein levels [70].  
It is also important to note that the physiological effects of miRNA target gene repression 
depend on tissue type. As each type of tissue has its own unique gene expression profile, 
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they also have their own specific set of miRNAs to regulate the post-transcriptional fate 
of those genes. 
MicroRNAs and the Brain 
The discovery of miRNAs led quickly to many high-throughput studies examining their 
unique profiles in multiple species and tissue types. Results from these early profiling 
studies recognized that miRNAs, just like mRNAs, can be tissue specific giving rise to 
the idea these specific miRNAs might play an important role for development or function 
of those specific tissues [73]. The initial studies identified miRNAs that were enriched in 
the brain, though they did not differentiate between brain regions or cell types. One 
example is miR-124, which was identified as a brain-specific miRNA since it was highly 
expressed in the brain and not in other tissues [73,74,75,76,77]. Subsequent profiling 
studies began to dissect the brain into discrete anatomical regions, and the results showed 
that miRNAs are indeed expressed in region-specific areas within the brain 
[78,79,80,81,82].  
MicroRNAs and Brain Development 
MicroRNAs were first discovered as regulators of embryonic development and further 
shown as necessary factors of tissue specific development [21,22,83]. One of the first 
studies generated a transgenic dicer-null zebrafish model [84]. These animals had failed 
brain development, however axis formation was not disturbed in the embryo [84]. 
Importantly, the authors were able to rescue normal phenotypic brain development by 
introducing miR-430, providing strong evidence that miRNAs are required for normal 
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brain maturation [84]. Mice lacking either dicer or DGCR8 (proteins critical for miRNA 
biogenesis) were also generated and both knockout mice resulted in an embryonic lethal 
phenotype [85]. However, these mice also displayed several abnormal brain 
morphologies: a deformed hippocampus, reduced size in the cortex, and increased 
neuronal cell death [85].  
Profiling studies examining miRNA expression across various developmental time points 
have all demonstrated a shift in miRNA expression as the brain develops in multiple 
species including zebrafish, mouse, non-human primates, and humans [86,87,88,89,90]. 
The alterations in miRNA expression coincide with mRNA and protein expression 
profiles as well, providing further evidence for a miRNA regulatory role in brain 
development [87].  
Neuron Specific MicroRNAs 
Profiling studies also identified specific miRNAs that are markers of developing neurons. 
For instance, miR-124 was shown to be a marker of mature neurons and miR-9 a marker 
of differentiating neurons [88]. It is important to note that miR-124 was also shown to 
decrease the expression of non-neuronal genes [91,92]. Analysis of miRNA expression in 
primary neuronal cell cultures and use of fluorescent in-situ hybridization (FISH) 
demonstrated a group of miRNAs that are specific to neurons: miR-124, miR-9, miR-
128, miR-29, let-7, and miR-26 [93,94,95]. The studies of miRNA expression in neurons 
also showed that miRNAs were not only localized to the soma (body) of the neuron, but 
also to the dendrites and synapses, suggesting that miRNAs could regulate local protein 
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synthesis at these distant sites [95,96]. While miRNAs were found to be equally 
distributed between the soma and dendrites, there were some miRNAs that were 
preferentially localized to the dendrites [95]. In support of these studies, argonaute 
proteins were also found to be localized to the dendrites, demonstrating that the key 
components of RISC were anatomically situated to facilitate miRNA regulation of 
mRNA targets in dendritic branches. Surprisingly, one of the key miRNA biogenesis 
proteins, dicer, was also found to be localized to the dendrites, and pre-miRNAs were 
found to be in the synaptic fractions [96,97]. Together, these results provide evidence that 
the pre-miRNA structures are actively trafficked to the dendrites where they are further 
processed to their mature forms through dicer cleavage.  
Neurons have the specialized capability of depolarizing their membrane and generating 
an electrical action potential. Neuronal communication occurs when the action potential 
reaches the synapse of a neuron to cause the release of neurotransmitters to depolarize the 
membrane of the adjacent neuron. The proteins involved in neurotransmission are highly 
dynamic, which suggests that miRNAs may play a role in their regulation. One of the 
first studies to demonstrate that miRNAs maybe be involved in neurotransmission 
showed that miRNA ribonucleic protein complexes (miRNP) and processing bodies (P-
bodies) re-localized to distant sites in the dendrites of neurons during neuronal activation 
[98,99,100]. These results were followed by observations that miRNA expression could 
be regulated by light in retinal neurons. Using tetrodotoxin (TTX) to block sodium 
channels, the authors demonstrated that miRNAs degrade much faster in retinal neurons; 
an observation which held for primary neuronal cultures isolated from the hippocampus 
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and cortex [101]. Another study demonstrated that depolarization of neurons increased 
miRNA expression of specific miRNAs in electroshocked mice [102]. Together these 
studies demonstrate that miRNAs in brain are sensitive to perturbations in the cellular 
environment and are likely involved in regulation of neuronal communication. 
MicroRNAs and Synaptic Plasticity 
Most early studies focused on the role of miRNAs during embryonic development, 
therefore the role of miRNAs in adult brain function was not clear. One of the first 
studies to explore the role of miRNAs in the adult brain used an inducible dicer knockout 
transgenic mouse model. Konopka et al. demonstrated that loss of dicer expression in the 
brain of adult mice resulted in increased learning and memory scores on the morris water 
maze [103]. The study also showed increased expression of BDNF (brain-derived 
neurotrophic factor) and MMP-9 (matrix metallopeptidase 9), critical regulators of 
synaptic plasticity, as a result of miRNA loss [103].   
The hippocampus is a region of the brain responsible for learning and memory, and has 
been the focus for the study of the regulation of synaptic plasticity. Two miRNAs, miR-
132 and miR-134, are highly expressed in the hippocampus [78]. miR-132 has been 
shown to be regulated by BDNF via CREB activation [104]. Overexpression of miR-132 
increases the likelihood of synaptic transmission in mouse hippocampal neurons while 
the knockout of miR-132 results in decreased dendritic arborization [104,105]. Together 
these studies show that miR-132 is a key regulator of synaptic plasticity. In addition, 
miR-134 is localized to the synapse in rat hippocampal neurons where it negatively 
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regulates the size of dendritic spines through the inhibition of a protein kinase, Limk1 
[106]. MiR-134 is regulated by the protein deacetylase, SIRT1. SIRT1 knock down 
results in increased miR-134 expression, decreased CREB and BDNF, and decreased 
synaptic plasticity [107].  These data demonstrate the power of miRNAs in regulating 
neuronal communication and brain physiology.  
MicroRNAs and Brain Aging     
Aging results in the dysregulation of normal processes resulting in a lower threshold for 
pathogenic process to occur. In particular, gene expression changes are significantly 
altered in advanced age, suggesting that there is dysregulation of gene expression. The 
first studies to look at miRNA expression during aging were done using C. elegans as a 
model [108,109]. Profiling miRNA expression during the span of the nematode’s life 
showed that nearly half of the 114 miRNAs analyzed were altered during the adult phase, 
suggesting a powerful regulatory role for miRNAs in aging [108]. Another study took the 
observation one step further and questioned whether miRNAs can directly regulate 
lifespan. The authors used C. elegans that were daf-2 (Insulin-like growth factor-1) 
mutants, which result in an extended lifespan, and identified which miRNAs were altered 
in expression as compared to wildtype nematodes [110]. Mutation of specific miRNAs 
identified in their screen resulted in alteration in the lifespan of the nematodes, suggesting 
that miRNAs can either positively or negatively regulate aging [110]. 
Aging studies were further extended to analyze miRNA expression in the aged brain. 
Expression profiles of miRNAs in the brains young and old mice identified three 
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miRNAs (let-7, miR-124, and miR-34) that were altered as a function of age [111,112]. A 
similar study identified miR-34a as a potential marker of brain aging in mice by 
demonstrating that its expression was increased in the brains of aged mice and also in the 
blood, suggesting that miRNAs could be used a convenient biomarker of brain aging in 
humans [113]. miRNA, mRNA, and protein expression were analyzed during embryonic 
development and aging in human and macaque brains. Somel et al. showed that the 
changes in miRNA/mRNA/protein that occurred during development were either 
reversed or extended into aging, suggesting that aging is a form of dysregulated 
development [114]. In particular, the study identified miR-124, miR-125a, miR-9, miR-
181a, and miR-29 as being altered with aging in the brain [114]. Age related changes in 
miRNA expression could also be identified in the blood of aged humans [115]. Taken 
together, these studies of gene and miRNA expression in the brains of non-human 
primates and humans during aging further cemented the universality of these age related 
changes in miRNA expression, and show that they can be used as potential biomarkers 
for the pathological conditions associated with the aging brain. 
Estradiol regulation of MicroRNA expression 
Many different extracellular signals regulate miRNA expression and the sex steroid 
hormone E2 is one of them. Estradiol regulation of miRNAs has been demonstrated in 
MCF-7 breast cancer cells, where E2 both enhances and represses miRNA expression 
depending on the specific miRNA [116,117,118,119,120]. Estradiol mediates its effects 
through two nuclear receptors called estrogen receptor α (ERα) and β (ERβ) [117,121]. 
24 
 
 
Both receptors are able to bind to the promoter regions upstream of a miRNA and induce 
transcription [117,121]. Importantly, breast cancer cell proliferation is mediated in part 
by E2-induced miRNA expression, which provides a molecular mechanism explaining 
the differences between ER negative and ER positive breast cancer phenotypes [122]. 
Interestingly, E2 regulation of miRNA expression in non-cancer tissues has not been 
extensively studied. The lack of research is surprising since E2 is an important regulator 
of many neurobiological processes. It is likely that regulation of miRNA expression is a 
key regulatory mechanism used by E2 to exert its pleiotropic effects on cognitive 
processes.  
In summary, the data to date strongly suggest that miRNAs as a plausible molecular 
mechanism mediating E2 effects on brain function. Further, the data suggest that aging 
could alter those effects on brain function, thereby providing a mechanistic explanation 
for reduced efficacy of E2 in postmenopausal women. The overall goal of this research 
project was to determine the effect of aging on E2-mediated regulation of miRNA 
expression and determine the mechanisms by which E2 regulates miRNA expression in 
the brain. Chapter 3 describes differences in E2 mediated regulation of miRNAs in young 
vs. aged brains and demonstrates both age- and brain-region specific effects of E2 on 
miRNA expression. Chapter 4 directly tests the timing hypothesis using an aged model of 
with varying lengths of ovarian hormone deprivation as well as defining the points in the 
miRNA biogenesis pathway regulated by E2 and aging. Chapter 5 directly describes the 
effect of aging on mature miRNA expression in non-ovariectomized female rats. Finally, 
chapter 6 attempts to replicate the in-vivo findings in an in-vitro setting. Taken together 
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the findings point to altered regulation of miRNAs with aging as an underlying factor in 
the reduced effectiveness of E2 in postmenopausal women. 
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CHAPTER III  
MICRORNAS IN THE AGING FEMALE BRAIN: A PUNITATIVE 
MECHANISM FOR AGE SPECIFIC ESTROGEN EFFECTS 
 
Introduction 
Advanced age is accompanied by global changes in neuronal gene expression. 
Recent studies have demonstrated that microRNA (miRNA) expression also changes with 
age, an intriguing correlation suggesting that age-related miRNA fluctuations could be 
responsible for modulating the overall change in global gene expression 
[108,109,111,112,114,123]. miRNAs are noncoding regulatory RNAs transcribed from 
intergenic or intragenic regions of the genome in a RNA polymerase II dependent manner 
[31,124].  Primary miRNA (pri-miRNA) transcripts are sequentially cleaved by the 
nuclear enzyme drosha, and the cytoplasmic enzyme dicer, to form the functionally 
mature single-stranded form of the miRNA [45,50,125]. Complementary binding of the 
mature miRNA to the 3’ untranslated region (UTR) of a target messenger RNA (mRNA), 
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and its subsequent association with the RNA-induced silencing complex (RISC), leads to 
mRNA translational repression and/or degradation [64,126,127]. Current efforts are 
focused on elucidating potential target genes that are regulated by miRNAs, however less 
is known about the upstream pathways that regulate miRNA expression, processing, and 
temporal activity in the brain.  
The gonadal steroid hormone 17β-Estradiol (E2) is one factor that has been shown 
to regulate miRNA expression and biochemical processing in some systems, such as 
cancer cell models [117,118,121,128,129,130]. Furthermore, E2 has been shown to be 
neuroprotective by decreasing the recovery time after stroke and improving learning and 
memory in aged rodents, primates, and humans, [131,132]; however, the beneficial 
effects observed in older women are largely dependent on the length of time between the 
onset of menopause and the administration of hormone therapy [4,133]. Consequently, 
the “timing hypothesis” suggests that the molecular mechanisms regulating E2 action are 
fundamentally changed during an extended hypo-estrogenic period [134,135,136], with 
aging being a further layer of complexity that alters these postmenopausal mechanisms.   
Numerous studies clearly show that aging has detrimental consequences for the 
hippocampus, a brain region that is required for learning and memory, as well as for 
mediating the physiological responses to perceived stressors.  Multiple excitatory 
signaling pathways, growth factors, and steroid hormones govern hippocampal neuronal 
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functions [137,138]. This brain structure has been extensively studied for its importance 
in memory formation, however hippocampal neurons also interact broadly with other 
brain regions to mediate a variety of more complex behaviors [139]. The hippocampus 
can be functionally divided into ventral and dorsal sub-divisions, which primarily 
mediate emotion/stress and memory/cognition, respectively [140]. In addition, these two 
divisions have distinct gene expression profiles, which are thought to delineate their 
specific functions [141,142]. Similarly, region-specific expression of miRNAs has been 
observed in the brain, suggesting that they have unique and specific neurological 
functions [74,75,78,79,80,81,131]. For instance, miRNAs have been shown to play a 
critical role in neuronal development, survival, and synaptic plasticity 
[91,103,104,105,106,107,143,144,145]. Consequently, disruption of miRNA activity has 
been associated with several neuropathological conditions such as Alzheimer’s disease, 
schizophrenia, and general mood disorders [146,147,148,149,150,151].  
In our studies, we hypothesized that E2 differentially regulates miRNA 
expression in the aged female hippocampus leading to altered gene expression important 
for neuronal function. To test our hypothesis, we compared the hippocampal miRNA 
expression profile of young (3 month) and aged (18 month) female rats that underwent 
surgically induced menopause (i.e., ovariectomy). Following a 7-day period of E2 
withdrawal, animals were then administered with E2 or vehicle (control) for 3 days. 
Global changes in miRNA expression in the ventral hippocampus were evaluated using a 
rat miRNA microarray. The analysis of global miRNAs confirmed the presence of brain 
region-specific miRNA composition. More importantly, our results also showed miRNA 
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changes to be E2 and/or aging-dependent. Furthermore, we identified potential miRNA 
target genes that are for: cognition/memory (i.e., sirtuin1 (SIRT1), brain-derived 
neurotrophic factor (BDNF)), stress (i.e., glucocorticoid receptor (GR)), and synaptic 
function (i.e., gamma-aminobutyric acid (GABA) A receptor 1 (GABRA1)). 
Collectively, our results showed that the loss of circulating levels of E2 results in a 
fundamental shift in the composition of  miRNA species in the aged brain, which may be 
one molecular mechanism that explains the “timing hypothesis”.  
 
Results 
E2 differentially regulated miRNA expression in the ventral hippocampus of aged female 
rats. 
Our first objective was to determine whether steady state miRNA expression in 
the ventral hippocampus (vHIPP) was altered by age (3 vs. 18 mo) and/or E2 
bioavailability. For this initial scan, we used a microarray platform that analyzed a total 
of 723 previously identified rat miRNAs of which 421 (58.2%) reached detectable levels.  
Figure 2A shows all of the miRNAs that reached a high threshold of detection and were 
significantly changed across all groups. Examination of the relative expression levels of 
the miRNAs expressed in the vHIPP revealed that the majority (288 miRNAs) are 
expressed at low (<500 SI) levels (Fig. 2A, Supporting Table 1). We refined our analysis 
to include only those miRNAs that were expressed at moderate to very high expression 
levels (133 miRNAs >500 SI). Many of the miRNAs that had high or very high signal 
intensity in our array, such as miR-9, have previously been shown to be highly expressed 
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in the brain and regulate important neuronal functions [78]. Interestingly, some passenger 
strand miRNAs (formerly denoted as miRNA*) were amongst the highest expressed 
miRNAs, supporting previous studies indicating a functional role for passenger strand 
miRNAs [56]. Notably, 58 additional miRNAs reached statistical significance, however 
the signal intensity was low (< 500 SI) and these miRNAs were excluded from further 
analysis. Of the subset that reached statistical significance and had a high signal intensity, 
34 were significantly altered by E2 treatment regardless of age, 21 were significantly 
altered by age alone, and 9 were altered by E2 dependent upon age (Fig. 3B). These 9 
miRNAs were chosen for further validation using qRT-PCR. Ventral hippocampal 
(vHIPP) samples taken from the right hemisphere (contralateral the side used for the 
microarray) were used to validate the 9 miRNAs that were differentially regulated by E2 
dependent upon age, as identified from the microarray. Of the miRNAs chosen for 
validation, miR-154 and miR-218 failed to reach statistical significance using qRT-PCR 
and were not pursued further. 
A significant interaction between treatment and age was observed for let-7i and 
miR-495 (Table 1), but not the other 5 miRNAs tested. However, a significant main 
effect of treatment was seen in 6 of the 7 miRNAs tested and a main effect of age was 
observed in 2 of 7miRNAs (see Table 1). E2 significantly increased (p<0.05, let-7i, miR-
7a, miR-9-3p, miR-125a, miR-181a) or decreased (miR-495) steady state expression 
levels of all of the 7 tested miRNAs in the old animals, whereas only miR-9-3p was 
increased in the young (Fig. 4A). Notably, the only miRNA that was decreased due to E2 
treatment in the vHIPP of either age group was miR-495 (Fig. 4A). Moreover, unique to 
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the vHIPP there were no significant changes in any of the seven E2-regulated miRNAs 
tested due to age alone (i.e. vehicle-treated). 
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Figure 217β-estradiol (E2) differentially regulates miRNA expression in the 
ventral hippocampus of young and old female rats. 
Heat maps depicting significantly regulated (p<0.05) miRNAs in the ventral 
hippocampus of A) 3 and 18 month old, B) 3 month old, and C) 18 month old female 
rats. The expression of an individual miRNA in each sample is shown using a color 
code where red and green represent high and low fold change respectively. Samples 
O1-O5 and Y1-Y5 represent 18 and 3 month vehicle treated animals respectively. 
Samples O6-O10 and Y6-Y10 represent 18 and 3 month E2 treated animals 
respectively. 
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E2 regulation of miRNA expression is brain region specific. 
 
 
 
Figure 3. Summary of expression levels and E2/Age regulated miRNAs in the 
ventral hippocampus of female rats. 
A) Pie chart depicting the number of miRNAs with very high (>20,000), high (10,000-
20,000), moderate (500-10,000), and low (<500) signal in the ventral hippocampus of 3 
and 18 month old ovariectomized female rats. B) A Venn diagram depicting the 
number of miRNAs regulated E2, age, and E2/age together by miRNA microarray 
analysis.  
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Similar to protein coding RNA species (i.e. mRNA), some studies have shown 
that miRNAs are expressed in a brain region-specific manner suggesting they might play 
an important role in the function of that particular brain region [75,78,81]. To determine 
whether E2 regulates the same miRNAs from the vHIPP in other brain regions, we 
examined three additional brain regions that are anatomically and functionally connected 
to the vHIPP: the dorsal hippocampus (dHIPP), the paraventricular nucleus of the 
hypothalamus (PVN), and the central amygdala (CeA). Across all brain regions E2 
significantly altered the expression levels of the greatest number of miRNAs tested in the 
vHIPP (2 in young animals, and 7 in old animals, Fig. 4A), whereas only 3-4 miRNAs 
were significantly changed following E2 treatment in each of the other 3 brain regions 
(Figs. 4B, 5A,B). Although we observed the greatest number of miRNA changes in the 
vHIPP, the largest magnitude (>12 fold increase) of E2-induced changes were in the 
dHIPP and CeA (Figs. 4B, 5B). Taken together, miR-7a was the only miRNA that E2 
consistently regulated in all 4 brain regions. 
Dorsal Hippocampus. Despite the anatomical proximity of the ventral and dorsal 
hippocampus, E2 effects in the dHIPP were substantively different from the vHIPP (Fig. 
4B). A significant interaction between age and treatment was observed for miR-7a 
(Supporting Table 2), but not the other 7 miRNAs tested. A significant main effect of 
treatment was observed for 2 out of 7, and a main effect of age for 5 out of 7 miRNAs 
tested (Supporting Table 2).  
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Figure 4. E2 regulation of miRNA expression in the ventral and dorsal 
hippocampus. 
Real time qPCR validation of miRNAs in the A) ventral hippocampus (vHIPP) and B) 
dorsal hippocampus (dHIPP) of 3 and 18 month old ovariectomized rats treated with E2 
or vehicle control. Results shown are mean fold change ± SEM as compared young 
vehicle treated animals. Data were analyzed by two-way ANOVA with age and 
treatments as factors. Dissimilar symbols indicate a statistically significant difference 
between groups (p<0.05). 
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Table 1. 2 way-ANOVA analysis of miRNA expression in the vHIPP 
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Interestingly, 3 of the tested miRNAs showed a significant age-dependent increase in the 
absence of E2 (miR-7a, miR-9, miR-181a, p<0.05, Fig. 4B), with miR-7a being increased 
by more than 12 fold by age alone. Notably, this observed age-related increase was 
completely abolished by E2 treatment in the old animals (Fig. 4B). Unlike in the vHIPP, 
miR-9 was significantly decreased by age alone (p<0.05), and E2 treatment did not 
further potentiate this effect (Fig. 4B). Similarly, miR-181a was significantly increased 
with age alone (p<0.01) and E2 had no additional effects (Fig. 4B). 
Paraventricular Nucleus (PVN). In the PVN, there was an significant interaction 
between treatment and age for miR-7a only, similar to what we observed in the dHIPP 
(Supporting Table 3). A significant main effect of treatment was observed for 4 out of 7, 
and a main effect of age for 4 out of 7 miRNAs tested (Supporting Table 3). Age alone 
induced significant increases in let-7i and miR-7a, both of which were either potentiated 
by E2 treatment (i.e. let-7i) or reversed to levels significantly below those observed in the 
young animals (i.e. miR-7a) (Fig. 5A). Similarly, E2 significantly increased miR-9 in the 
old animals as compared to the young (Fig. 5A).   miR-125a was not altered due to age 
alone, however treatment with E2 significantly increased miR-125a in the young, but did 
not increase it by the same magnitude in the old PVN (Fig. 5A).  
Central Amygdala (CeA). In the CeA there was a significant interaction between 
treatment and age in 3 of the 7 miRNAs (Supporting Table 4). Main effects of treatment 
and age were seen in 1 of 7, and 3 of 7, miRNAs, respectively (Supporting Table 4).  
 
40 
 
 
 
 
Figure 5.  E2 regulation of miRNA expression in the PVN and CeA. 
Real time qPCR validation of miRNAs in the A) paraventricular nucleus of the 
hypothalamus (PVN) and B) central amygdala (CeA) of 3 and 18 month old 
ovariectomized rats treated with E2 or vehicle control. Results shown are mean fold 
change ± SEM as compared young vehicle treated animals. Data were analyzed by two-
way ANOVA with age and treatments as factors. Dissimilar symbols indicate a 
statistically significant difference between groups (p<0.05). 
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Post hoc analysis showed that E2 significantly altered 1 miRNA in the young animals, 
and 3 miRNAs in the old animals (Fig. 5B). The analysis revealed a significant decrease 
in miR-7a due to age alone and this “old” phenotype was mirrored in the young animals 
following E2 treatment (p<0.01, Fig. 5B.) Notably, the CeA is the only brain region 
where we observed a significant E2-mediated effect (decrease) on miR-7a in the young 
animals (Fig. 5B). Both miR-9 and miR-9-3p were  significantly increased by E2 in the 
old animals but not in the young (Fig. 5B). Finally, there was a significant age-related 
increase in miR-495 (p<0.001), which was significantly potentiated following E2 
treatment (Fig. 5B). 
E2 had no effect on miRNA processing in the ventral hippocampus 
 To begin to define the molecular mechanisms for E2 regulation of miRNA in the 
ventral hippocampus, we measured three components of miRNA processing and 
regulation pathways: drosha, dicer, and argonaute 2 (AGO2) in our young and old 
animals. Our results showed that E2 treatment had no statistically significant effect on the 
steady-state expression levels of any of these genes in the ventral hippocampus in either 
age group (Fig. 6), although there was a strong trend for an E2-mediated increased dicer 
expression in the young animals.  
E2 regulated miRNA predicted target genes important for neuronal function. 
In order to understand the physiological impact of these E2 regulated miRNAs, 
we analyzed potential mRNA targets for each miRNA using four different  target 
prediction programs (DIANA-mirpath, Targetscan, microRNA.org, and MicroCosm) 
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[152,153,154,155,156]. The predicted gene targets were represented in several cellular 
pathways including neuronal specific pathways, such as long term potentiation and axon 
guidance (Fig 7). Putative targets were chosen for testing in our ventral hippocampal 
tissue samples based on their known role in neuronal function and their algorithm score, 
as determined by the computer modeling programs (Fig. 8A). Degradation of mRNA 
transcripts is one mechanism whereby miRNAs decrease the protein expression of their 
target genes [64,126] and previous studies have demonstrated an inverse correlation of 
miRNA expression with their target mRNA expression [114]. To determine if there was 
an inverse correlation between the E2 regulated miRNAs in the ventral hippocampus and 
their predicted targets, we measured SIRT1, GR, BDNF, and GABRA1 mRNA 
expression. Consistent with our expected outcomes, SIRT-1 mRNA expression was 
significantly decreased in the ventral hippocampus of young animals (Fig. 8B) which 
inversely corresponded to SIRT1 predicted miRNAs, miR-9 (Figs. 4A, Fig. 8B). 
Moreover, E2 significantly increased GR mRNA levels in the young animals, although 
miRNA-181a was unaffected by E2 in that same age group, suggesting that multiple 
miRNAs could target GR. E2 had no effect on GABRA1 or BDNF mRNA expression at 
either age (Fig. 8B), although there was a strong trend for an E2-mediated increase in 
BDNF in the young animals. 
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Figure 6. miRNA processing enzymes are not affected by E2 treatment. 
Real time qRT-PCR analysis of drosha, dicer, and argonaute 2 in the A) 3 month and B) 
18 month old ventral hippocampus. Results shown are mean fold change ± SEM as 
compared young vehicle treated animals. Data were analyzed by one-way ANOVA with 
treatment as a factor. No significant differences were noted (p>0.05) 
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Figure 7.  Predicted cellular pathways of potential target genes 
of identified miRNAs. 
DIANA-mirpath was used to predict KEGG cellular pathways 
impacted by potential target genes of significantly regulated 
miRNAs in the ventral hippocampus of female rats. Results are 
depicted as the number of genes targeted by miRNAs (y-axis) in 
each cellular pathway (x-axis). 
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Figure 8.  Predicted gene targets of identified miRNAs are regulated by E2. 
A) Table of predicted miRNA gene targets determined based on algorithm scores of three 
computer prediction programs: Targetscan, microRNA.org, and MicroCosm; B) real time 
qPCR for sirtuin 1 (SIRT1), glucocorticoid receptor (GR), gamma-aminobutyric acid 
receptor A1 (GABRA1), and brain-derived neurotrophic factor (BDNF) in the 3 month, 
and C) 18 month old ventral hippocampus. Results shown are mean fold change ± SEM 
as compared young vehicle treated animals. Data were analyzed by one-way ANOVA 
with treatment as a factor. * indicates statistically significant difference (p< 0.05). 
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Summary 
Two novel findings emerged from these studies. First, we demonstrated that E2 is 
a critical regulator of mature miRNA expression levels in the brain and that the 
magnitude of E2 action differs according to specific brain regions. Second, we showed 
that even within a specific brain region, the effects of E2 on miRNA levels are temporally 
distinct. To our knowledge this is the first evidence demonstrating E2 regulation of 
miRNA expression in the brain and it suggests that this may be an important mechanistic 
pathway for E2 modulation of neuronal target genes resulting in a “fine tuning” of gene 
expression. This concept of “fine tuning” has gained critical recognition as an important 
determinant of cellular function and is especially vital in the brain, as communication 
between neurons requires rapid modulation of gene expression at the synapses where 
local translation of proteins is crucial.  
Our data underscore the concept that E2 can have completely different actions in 
an aged system compared to a young, although more time points are needed to ascertain 
the linearity of these changes. Overall, we observed significant interactions between age 
and E2 treatment for 5 specific miRNAs: Let-7i, miR-7a, miR-9, miR-9-3p, and miR-
495. These results highlight a potential molecular mechanism to explain the fundamental 
tenet of the timing hypothesis, namely that E2 has differential physiological effects 
dependent on age. Interestingly, most of the brain regions had unique miRNAs that were 
significantly affected by both age and treatment with the notable exception of miR-7a, 
which was altered in 3 of the 4 brain regions analyzed. Putative gene targets for miR-7a 
include SIRT1, which is critically important for mediating anxiety and memory, among 
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other things [107,157]. The timing hypothesis also posits that the length of time between 
menopause and subsequent hormone therapy dictates the nature of E2 action. In our 
study, we measured a relatively short time frame between surgically-induced menopause 
and hormone replacement (i.e. 7 days) and the changes we observed might vary greatly 
under conditions with longer periods of E2 withdrawal. Longer periods of E2 withdrawal 
can alter multiple factors including estrogen receptor (ER) levels. ERalpha has been 
shown to physically associate with drosha and participate in the maturational processing 
of several miRNAs [12]. Therefore, the length of E2 deprivation could have a significant 
impact on the expression of mature miRNAs leading to differential gene target expression 
profiles. Another important observation from these data was the revelation that large-
scale global changes in miRNA expression levels were not observed, as only a small 
subset of the total 723 miRNAs were altered by age and hormone treatment. These results 
suggest that most miRNAs are likely key regulators of fundamental cellular processes 
which could be detrimental to have under the control of fluctuating steroid hormones.  
The primary focus of our study was to determine the effects of E2 on miRNA 
expression between young and old animals, however the data revealed several miRNAs 
that were regulated by age alone. Importantly, our data show for the first time that age-
dependent miRNA expression varied across brain regions, suggesting that the brain does 
not age uniformly. For instance, none of the miRNAs that we tested were significantly 
increased by age alone in the vHIPP. This observation was sharply contrasted by the 
results from the other 3 brain regions that each had 2 or 3 miRNAs that were regulated by 
age alone. Perhaps the most striking of these were the results of miR-7a, which had a 12-
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fold increase in the old dHIPP compared to that of young animals. Interestingly, this 
magnitude of effect was not observed for miR-7a in any of the other brain regions, 
suggesting that miR-7a could have significant biological consequences for dHIPP 
function in old animals. The majority of studies that have investigated age dependent 
changes in mRNA and/or miRNA have been analyzed in only one brain region 
(prefrontal cortex) or in the entire brain as a whole [158,159,160,161,162,163]. While 
these studies have provided important observations of age-dependent gene expression 
changes in the brain, the conclusions relating to brain region-specific functions and/or 
pathologies are limited by the brain samples used.  
One of the more intriguing findings from our study was the observation that E2 
differentially regulated miR-9 and miR-9-3p. These two functionally mature miRNAs are 
derived from the same primary miRNA transcript (pri-miRNA), yet typically one strand 
of the cleaved duplex is preferentially recruited to the RISC complex and becomes the 
biological effector, while the other strand undergoes degradation. Since the two strands 
are inverse complements, it is likely that they have vastly discrepant target genes and 
several studies have demonstrated biologically functional roles for selected miRNA 
passenger strands [164,165]. In our studies, E2 decreased miR-9 expression in the dorsal 
hippocampus of 3 month old animals, while simultaneously increasing the expression of 
miR-9-3p. Conversely, by 18 months of age miR-9-3p was no longer significantly 
regulated by E2, yet the E2-induced reduction of miR-9 remained the same. The 
differential regulation of miR-9 and miR-9-3p suggest that a separate cohort of target 
genes may be affected in the aged ventral hippocampus, which could have a significant 
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impact on the hippocampal-mediated control of emotion/stress. Since miR-9/9-3p 
sequences are on the same primary miRNA transcript, it stands to reason that E2 
regulates the processing of the pri-miRNA to favor the retention of miR-9-3p sequence 
over the miR-9 in the young brain. The miR-9-3p strand selection likely occurs after the 
enzyme dicer has cleaved the precursor miRNA (pre-miRNA) to form the mature miRNA 
duplex since the mature miRNA duplex still contains both miR-9/9-3p sequences. 
Therefore, one possibility is that E2 facilitates the retention of miR-9-3p by the RISC 
complex longer than miR-9. Alternatively, E2 could mediate the active degradation of 
miR-9, but not miR-9-3p however, the mechanisms by which miRNAs are targeted for 
degradation are still largely unresolved.  
The pleotropic nature of E2 action suggests that the mechanisms underlying those 
actions are equally diverse. Conventional views dictate that a majority of E2 effects are 
due to direct transcriptional regulation of target genes. Consequently, the precise 
molecular mechanisms that mediate E2 actions on miRNA expression levels remain 
unresolved, especially in the in vivo system. One possibility is that E2 regulates miRNA 
processing, through modulation of key enzymes such as drosha or dicer, or by altering 
components of the RISC complex, such as argonaute 2. In our studies, E2 did not causes 
significant changes in any of these parameters.  These observations led us to hypothesize 
that that E2 might act directly at the promoter level to modulate pri-miRNA transcription. 
E2 actions are mediated primarily by two high-affinity nuclear receptors, estrogen 
receptor alpha and beta (ERα, ERβ), and both subtypes are expressed in the ventral 
hippocampus, although ERβ is expressed at higher levels and in different hippocampal 
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divisions compared to ERα [166,167,168]. Moreover, the temporal expression of ER 
subtypes in the brain has been well documented [164,169] and it is exciting to postulate 
that some of the differential E2-mediated effects on miRNA expression are due to age-
related changes in ER subtype expression. Interestingly, previous studies have shown that 
E2 can act through both estrogen receptor subtypes to regulate miRNA expression in 
cancer cell models [121,130].  In these cell models, E2 has been shown to not only 
regulate miRNA transcription, but also to play a role in the processing of the miRNAs via 
direct ERα interaction with components of the drosha processing complex [130].  
The functional relevance of miRNAs is the focus of intensive investigation and, 
as such, defining the specific targets for these miRNAs is of paramount importance. We 
identified miRNAs uniquely regulated by E2 and then used computer prediction 
algorithms to pinpoint putative target genes. Sirtuin 1 (SIRT1), which is a protein 
deacetylase that first gained recognition for its effects on longevity [170,171,172] was 
identified as such a target gene. Recent research also showed that SIRT1 to be important 
for energy balance, memory, anxiety, and neuroprotection in the brain [107,157]. Our 
data demonstrated an inverse correlation between miR-9 and SIRT1 expression at 3 
months, which is consistent with a recent report revealing a complementary region on the 
SIRT1 3’ UTR with the miR-9 seed sequence [173]. Two other putative miRNAs that 
target SIRT1 is miR-7a and miR-495. Compared to any miRNA tested our data showed 
that miR-7a and miR-495 had the largest magnitudes of age-dependent change (i.e., 
greater than 12 fold increase).  Strikingly, E2 treatment completely abolished the age-
related effect on miR-7a. This observation is in line with recent evidence in steroid 
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hormone-regulated cancer models suggest that SIRT1 interacts with the estrogen receptor 
to regulate transcriptional activity [165]. Overall, our observations raise the possibility 
that E2 activated estrogen receptors may be another pathway whereby SIRT1 activity is 
regulated in the brain. Other predicted gene targets in this study, such as GR and 
GABRA1, did not show a direct correlation between their expression level, and the 
miRNA expression level. This observation may indicate that the E2-regulated miRNAs 
induced translational repression, as opposed to degradation of their target mRNA 
transcripts. The mechanism that leads to miRNA-mediated mRNA degradation or 
translational repression is not well understood, though it is clear that both processes are 
equally viable mechanisms of miRNA action on their target genes [12,174,175]. Taken 
together, our data clearly indicate that E2-regulated miRNA expression in the brain is 
age- dependent and the predicted targets of these miRNAs have important implications 
for neuronal function. Further validation of these and other potential targets are 
necessary, as predicative algorithms are not well developed enough to accurately predict 
true targets of miRNAs.  
While our data show that E2- regulated miRNA expression is altered in the aged 
brain as opposed to the young brain, it is not certain at this time whether this is 
dysregulation that would result in a net increase in adverse effects or protective 
mechanisms. The in vivo paradigm presented here offers a broad picture of the impact E2 
has on miRNA expression in the brain and how those effects might be altered by aging. 
There are inherent limitations using an in vivo paradigm, many of which preclude 
elucidating the precise molecular pathways of E2 action. Overall our data reveal a novel 
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temporal and neuroanatomical-dependent regulation of miRNAs by E2, thereby 
furthering our understanding of the complex mechanisms for E2 in regulating neuronal 
functions. 
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CHAPTER IV  
PROLONGED ESTROGEN DEPRIVATION ALTERS THE 
EFFECTS OF 17β-ESTRADIOL ON MATURE MICRORNA 
EXPRESSION IN THE AGED FEMALE RAT HYPOTHALAMUS 
 
Introduction 
 The average life expectancy has increased over the past century due to better 
living conditions and medical advancements [1]. Women in particular are living longer, 
yet the age of menopause has remained constant at approximately 50 years of age. This 
results in most women living nearly a third of their lives without high levels of 
circulating estrogens. Risk factors for many diseases, such as cognitive and mood 
disorders, increase in women following menopause [5,6,176] and these risk factors have 
been correlated with the sharp decline in circulating levels of estrogens. Hormone therapy 
(HT) is often prescribed for women to mitigate many of the adverse symptoms associated 
with menopause, based primarily on evidence from animal models demonstrating that 
estrogens are anxiolytic and increase cognitive function [12,13,131,132,177,178]. Data 
from studies in postmenopausal women, however, are less convincing that HT is 
beneficial. For instance, results from the large-scale clinical trial (Women’s Health 
Initiative (WHI)) showed that there was a temporal discrepancy in the beneficial efficacy 
of HT [3,4,5,6,7,16,133,179,180]. The beneficial effects were largely dependent on the 
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length of time following menopause onset that women received HT, with younger 
women realizing the greatest benefits. Follow up studies have since revealed that timing 
of HT is critical, both for maximum benefits, as well as minimal detrimental effects 
[3,7,16,133,179,180].  However, the molecular mechanisms underlying these age-
dependent effects of estrogens are unknown. 
Estrogens regulate gene transcription primarily through binding to estrogen 
receptors (ERs), which then act as transcription factors on gene promoters. However, 
estrogens have also been shown to regulate gene expression at the post-transcriptional 
level through microRNAs (miRNAs). miRNAs are a class of small non-coding RNAs 
that regulate gene expression via translational repression of target mRNAs [64,127], 
thereby decreasing the protein products of those genes. The miRNA biogenesis pathway 
reveals several potential regulatory points for estrogens. First, miRNAs are transcribed 
from the genome raising the possibility of ER-mediated regulation of miRNA 
transcription. Second, they are highly regulated post-transcriptionally by a series of 
RNase III enzymes, which sequentially cleave the primary transcript (pri-miRNA) into 
shorter fragments, and these enzymes act in conjunction with several cofactor proteins, 
some of which are regulated by estrogens [31,43,45,46,52,53,129,181]. Finally, the 
mature 22 nt miRNA duplex dissociates such that one strand (guide strand) is loaded onto 
an argonaute (AGO) protein, thereby forming the RNA-induced silencing complex 
(miRISC). The guide strand is largely protected from degradation due to its association 
with target mRNA and AGO, yet the passenger strand is typically degraded. Therefore, 
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miRNA degradation is another potential point for estrogens regulation of miRNAs.  The 
half-life of miRNAs can vary from minutes to days [151,182,183], yet the precise 
mechanisms regulating their stability are unclear. Several studies have shown that 
miRNAs are subject to post-transcriptional modifications, which can affect their stability. 
For instance, poly(A) polymerase associated domain 4 (PAPD4) is a 
nucleotidyltransferase that adenylates the 3’ end of miRNAs [184,185]; this modification 
to the miRNA can increase its stability and alter its ability to bind to the RISC complex 
[184,185]. Ultimately, miRNAs are degraded by at least one known exonuclease, 5’-3’ 
exoribonuclease 2 (XRN2) [186]. To our knowledge, there have been no studies to date 
demonstrating whether estrogens regulate any proteins that are involved in miRNA 
stabilization pathways.    
In the brain, miRNAs display both an age-and brain region-specific expression 
pattern, suggesting that they play critical roles in normal brain function 
[74,75,78,81,82,111,123]. Indeed previous studies have demonstrated that miRNAs are 
crucial for neuronal development and synaptic plasticity, and are also implicated in 
regulating affective behaviors [104,105,146,147,150,187,188,189]. Previously, our 
laboratory demonstrated that the major circulating estrogen, 17β-estradiol (E2), regulates 
miRNAs in an age- and brain region-dependent manner in female rats, suggesting that 
there would be differential mRNA translation in those brain regions at varying ages due 
to E2 dependent miRNA regulation [190]. E2 exerts its effects through two estrogen 
receptors, ERα and ERβ. ERα and ERβ display brain region specific expression patterns, 
and also have dichotomous effects on brain function [191,192]. Additionally, both 
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receptors have been shown to regulate miRNA expression in in-vitro conditions, however 
it is not known whether one or both receptors are required for mediating E2-induced 
miRNA expression in the brain [117,121].  
We propose that there is a biological switch in estrogens’ actions that occurs 
coincident with age and length of time after ovarian hormone depletion, and we 
hypothesize that age dependent regulation of miRNAs could be the molecular basis for 
that switch. Our previous work showed that E2 differentially regulated miRNA 
expression in the brain of young (3 mo.) compared to aged (18 mo.) female rats. In this 
current study we extended those observations by investigating if longer periods of E2 
deprivation in aged female rats altered the E2-dependent regulation of miRNAs we 
previously observed in the brain. Female Fisher 344 rats (18 mo. old) were 
ovariectomized (OVX) and then given an acute E2 treatment at 1, 4, 8, or 12 weeks post-
OVX. We analyzed the expression of our previously identified E2 regulated mature 
miRNAs, as well as their intermediary biosynthetic products (pri-miRNA, pre-miRNA) 
in the hypothalamus. In addition, we quantified the expression of several miRNA 
processing proteins including drosha, DiGeorge syndrome critical region 8 (DGCR8), 
exportin-5 (XPO5), dicer, AGO2, XRN2, and PAPD4. Finally, we determined which ER 
mediates the E2-induced increase in miRNA expression observed at 1 wk. post-OVX in 
the aged female brain. Collectively our results show that extended deprivation of ovarian 
hormones markedly alters E2 regulation of mature miRNAs in the aged female 
hypothalamus, suggesting that there is a shift in how the brain responds to the re-
introduction of E2 after prolonged periods of ovarian hormone deprivation.       
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Results 
Treatment with E2 fails to regulate mature miRNA expression following longer periods 
of ovarian hormone deprivation.  
We developed an animal paradigm to directly test the timing hypothesis in aged female 
rats. Aged rats (18 mo., equivalent to 55 years old in human) were ovariectomized 
(OVX) to model surgically induced menopause and eliminate the source of all ovarian 
hormones. Acute administration of E2, or vehicle control, was given following varying 
lengths of time post-OVX: 1, 4, 8, or 12 weeks (Fig. 9A). Animals were euthanized 24 
hours after the last injection, brains rapidly removed, and total RNA isolated from the 
hypothalamus. Next, we measured the expression levels of mature let-7i, miR-7a, miR-9, 
miR-9-3p, miR-125, miR-181a, and miR-495 using qRT-PCR (Fig 10A-G). We had 
previously identified these 7 miRs as being regulated by E2 in an age dependent manner 
[190]. A two-way ANOVA analysis determined that there was no statistically significant 
interaction between treatment and length of ovarian hormone deprivation, indicating that 
the two factors were independent. However, analysis of treatment within each time point 
demonstrated that E2 significantly increased the expression of mature let-7i, miR-7a, 
miR-9, miR-9-3p, and miR-181a at 1 week post-OVX, (consistent with our previous 
published data, [190] but not any other time point (Fig. 10A-D, F, gray line, denoted by 
*). Interestingly, E2 treatment significantly decreased miR-495 at 12 weeks post-OVX, 
which was the only miRNA tested that showed an E2-mediated decreased expression 
(Fig. 10G).  
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One-way ANOVA analyses across the deprivation time points showed that six of the 
seven miRNAs (let-7i, miR-9, miR-9-3p, miR-125a, miR-181a, and miR-495) were 
significantly increased due to age alone (Fig. 10, black line, denoted by #). Specifically, a 
post-hoc analysis showed that let-7i expression was increased at 12 weeks post OVX 
(Fig. 10a black line,#) in vehicle treated animals. Similarly, miR-9, miR-9-3p, miR-125a, 
miR-181a, and miR-495 were significantly increased in both vehicle and E2 treated 
animals at 8 and 12 weeks post OVX (Fig. 10C-G, black line, #). 
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Figure 9. Ovarian hormone deprivation paradigm. 
a) Schematic representation of the animal experimental paradigm. Fischer 344 female rats were 
obtained at 18 months of age and ovariectomized. Rats were given a subcutaneous injection 
once/day for 3 days 1, 4, 8, or 12 weeks post-OVX (N=6/age/treatment). b) E2 plasma 
concentrations assayed by ELISA from blood samples taken 24 hours after the last injection of 
E2. Data displayed as mean ± SEM pg/mL. 
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Figure 10. E2 regulation of mature miRNA expression in the hypothalamus after 
increasing lengths of ovarian hormone deprivation. 
a-g) Mature miRNA expression was analyzed by real time qRT-PCR and displayed as mean ± 
SEM fold change as compared to 1 week vehicle treated animals (N= 6/age/treatment). An * 
denotes a statistically significant effect of treatment within a time point. Different symbols 
(#,%) denote a statistically significant difference across time points. 
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Mature miRNA expression levels are not paralleled by the expression of their pri- and precursor 
forms. 
 
Effects of E2 treatment on primary miRNA (pri-miR) expression levels in the 
hypothalamus. 
The data from the initial experiments were consistent with our previously published 
findings and demonstrated that E2 regulates mature miRNA expression following short-term, but 
not long-term, OVX. We next analyzed the expression of their primary and precursor transcripts 
using qRT-PCR to determine the level of the biosynthetic pathway that E2 acts to regulate these 
mature miRNAs. Similar to the results of the mature miRNAs, a two-way ANOVA analysis 
revealed that there was no significant interaction between treatment and age for the pri- or 
precursor forms of these miRNAs. Moreover, analysis of treatment within a single time point 
showed that showed that E2, in general, had no effect on the transcription of most of the pri-
miRNAs at any time point (Fig. 11). However, there were a few exceptions. Specifically, 
comparison of treatment within a time point revealed that E2 significantly increased expression of 
the primary miRNA transcript of let-7i one-week post OVX, but not at any other time point (Fig. 
11A, gray line, *). Also, it is important to note that two of the mature miRNAs, miR-7a and miR-
9, are transcribed from multiple chromosomes, allowing for unique regulation of biogenesis at 
each locus. Therefore, we designed primers corresponding to distinct primary sequences on each 
chromosome for miR-7a and miR-9, in order to account for possible differences between mature 
miRNA products derived from the different chromosomes. Interestingly, these data revealed a 
switch in E2 regulation of each chromosome depending on the age post-OVX. Specifically, E2 
increased pri-miR-7a transcribed from chromosome 1 at 4 weeks post-OVX, but not any other 
time points (Fig. 11B, pri-miR-7a-1, gray line, *). Meanwhile, E2 significantly increased pri-
miR-7a transcribed from chromosome 17 at 1 week post-OVX (Fig. 11C, pri-miR-7a-2, gray line, 
*). These data suggest that the mature miR-7a product was derived from different chromosomes 
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depending on the time point. Interestingly, however, our data only showed a significant increase 
in mature miR-7a at the one-week time point, which points to chromosome 17 as potentially more 
important than chromosome 1 for E2-regulated mature miR-7a expression.  
Figure 11D-F depicts results from pri-miR-9. It is important to note is that miR-9 (guide strand) 
and miR-9-3p (passenger strand) are derived from the same primary and precursor transcripts 
which are located on two different loci on chromosome 1 (pri-miR-9-1, pri-miR-9-2) and one 
locus on chromosome 2 (pri-miR-9-3). Our previously published data showed that E2 
significantly regulated both the guide and passenger strands of mature miR-9 [190]. Analysis of 
the primary miR-9 expression showed that E2 treatment significantly increased pri-mir-9-1 and 
pri-mir-9-2 at 1 week post OVX, as well as pri-mir-9-2 at 4 weeks post OVX (Fig. 11D,E, gray 
line, *). By sharp contrast, E2 did not affect the expression levels of pri-mir-9-3 at any time point 
(Fig. 3F, gray line, *). Finally, E2 had no effect on pri-miR-181a or pri-miR-495 at any time point 
(Fig. 3H, I). 
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Figure 11. E2 regulation of the primary miRNA expression in the hypothalamus 
after increasing lengths of ovarian hormone deprivation. 
A-I) Primary miRNA expression was analyzed by real time qPCR and displayed as fold 
change as compared to 1 week vehicle treatment animals (N= 6/age/treatment). (*) 
denotes a significant effect of E2 as compared vehicle treated animals with in that time 
point (Student’s t-test). Different symbols (#,%) denote a significant difference between 
each time point (One-way ANOVA). 
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Effects of aging on primary miRNA (pri-miR) expression levels in the hypothalamus. 
One way ANOVA analyses across the deprivation time points showed that pri-
mir-7a-2, pri-mir-9-1, pri-mir-125a, pri-mir-181a, and pri-mir-495 were all significantly 
altered by age alone, and in general, they were all decreased with age (Fig. 11, black line, 
#). Specifically, expression levels of pri-mir-9-1 (Fig. 11D, black line, #) were 
significantly decreased at 8 weeks post OVX, while pri-mir-125a expression was 
decreased at 12 weeks post OVX (Fig. 11G, black line, #). Further, both primary 
transcripts for miR-181a and miR-495 were significantly decreased at 4, 8, and 12 weeks 
post OVX (Fig. 11H-I, black line, #). The only exception was for pri-mir-7a-2, which 
was significantly decreased at 4 weeks, but then increased at 8 weeks post OVX (Fig. 
11C, black line, #). 
Effects of E2 treatment and aging on precursor miRNA (pre-miR) expression levels in 
the hypothalamus. 
A two-factor ANOVA analysis revealed that there was no significant interaction 
between age and treatment for any of the precursor miRNAs, again suggesting that the 
two factors are independent. Next, statistical analyses within each separate time point 
demonstrated that E2 treatment significantly altered the expression levels of 3 out of 7 
pre-miRNAs tested when compared to vehicle-treated controls (Fig. 13, gray line, *).  
Interestingly, E2 treatment significantly increased the expression of pre-miR-7a-2 at both 
1 and 12 weeks post-OVX, but had no effect on pre-miR-7a-1 at any time point (Fig. 
13B,C, gray line, *).  
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Figure 12. E2 regulation of the precursor miRNA expression in the hypothalamus 
after increasing lengths of ovarian hormone deprivation. 
A-G) Precursor miRNA expression was analyzed by real time qPCR and displayed as 
fold change as compared to 1 week vehicle treatment animals (N= 6/age/treatment). (*) 
denotes a significant effect of E2 as compared vehicle treated animals with in that time 
point (Student’s t-test). Different symbols (#,%) denote a significant difference between 
each time point (One-way ANOVA). 
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These results sharply contrast what was observed with the primary transcripts of 
these same miRNAs (see Fig. 12B,C), suggesting that E2 acts differently at multiple 
levels of the miRNA biogenesis pathway. Similarly, the effects of E2 treatment were 
strikingly differently for pre-miR-9 (Fig. 13D) compared to its effects on the primary 
form (pri-miR-9; see Fig. 12D-F). Specifically, E2 significantly decreased pre-mir-9 
expression at 1 week post OVX, but then significantly increased its expression at 12 
weeks post OVX (Fig. 13D, gray line, *). While the primary transcript of miR-9 is 
transcribed from three different loci (hence, pri-miR-9-1, pri-miR-9-2, and pri-miR-9-3), 
the precursor hairpins generated from each primary transcript are too similar to be able to 
differentiate them using qRT-PCR. Therefore, it is possible that there were offsetting 
changes in each precursor form that might have obscured the final results. Interestingly, 
E2 completely abolished the steep age-related increase in pre-miR-181a observed at 4 
weeks post-OVX (Fig. 13F, gray line, *). These results were unexpected given the E2-
induced increase in both mature and pri-miR-181a expression levels at varying time 
points (see Figs. 11F and 4h). Finally, there were no effects of aging alone on the 
expression levels for any of the precursor miRNAs tested (Fig. 13, black lines).  
E2 and age-related changes in mature miRNA expression are not explained by 
concomitant changes in the mRNA or protein levels of key components involved in 
miRNA biogenesis. 
Our data show that E2 regulates miRNA expression at various levels along the 
miRNA biosynthetic pathway, raising the possibility that E2 could regulate the 
transcription (mRNA) and/or protein levels of critical components required for miRNA 
biosynthesis. Therefore, we analyzed the mRNA expression of the nuclear proteins 
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drosha and DGCR8 (key components of the microprocessor complex), as well as 
cytoplasmic proteins dicer, AGO2, XPO5, XRN2, and PAPD4 in the hypothalamus of 
animals subjected to our ovarian hormone deprivation paradigm (Fig. 14). The statistical 
analysis revealed that there was a significant interaction of treatment and age on the 
mRNA expression levels of drosha, but not any of the other genes tested (F(3,38)=3.762, 
p=0.019). Specifically, the post hoc analysis revealed that E2 treatment increased drosha 
mRNA expression at 8 weeks post OVX (Fig. 14A). Statistical analyses within each time 
point revealed that E2 treatment also increased DGCR8, dicer, and AGO2 mRNA 
expression levels at 8 weeks post OVX (Fig. 14B-D). Conversely, E2 treatment 
significantly decreased XPO5 at 1 week post OVX (Fig. 14E). We did not observe any 
significant changes in the mRNA expression XRN2 and PAPD4 between treatment 
groups at any time point (Fig. 14F, G, gray line). Moreover, we did not observe changes 
due to age alone in the mRNA expression of these genes (black lines).  
Next, we compared the mRNA levels of drosha, DGCR8, dicer, AGO2, XPO5, 
XRN2, and PAPD4 with their translated protein levels from the same animals (Figs. 15-
16). Interestingly, there was no statistically significant effect of treatment or age on the 
protein levels of any of these genes, despite our observed statistically significant changes 
in mRNA levels. These data suggest that E2-mediated changes in mature miRNA 
expression levels cannot be explained by mRNA/protein changes in these key miRNA 
biosynthetic components.  
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Figure 13. Regulation of miRNA biogenesis genes by E2 and ovarian deprivation. 
A-G) mRNA expression of miRNA biogenesis genes was analyzed by real time RT-PCR (N=6 
treatment/age group). Data is displayed as fold change as compared to 1 week vehicle treated 
animals.  
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Figure 14. Western blot analysis of miRNA biogenesis gene expression. 
A-D) 60µg of protein was run on a 10% PAGE. Images are representative blots (N=3/treatment 
group). Β-actin expression was used as the loading control. 
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Figure 15. Estradiol and ovarian hormone deprivation does not regulate miRNA 
biogenesis protein expression. 
A-D) Densitometry analysis of western blot images (Fig. 17) using BioRad Image lab software. 
Data are displayed at percent change as compared to vehicle treated animals (N=6 /treatment/age 
group). 
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ERβ mediates E2 effects on mature miRNA expression in the Hypothalamus 
The effects of E2 are mediated primarily by two estrogen receptors, ERα and 
ERβ, and both have been shown to regulate miRNA expression in cancer cell lines 
[116,117,121]. To determine which receptor mediates the regulation of miRNA 
expression in the aging female brain, we first examined the expression levels of ERα and 
ERβ mRNA in our ovarian hormone deprivation paradigm. A two-way ANOVA analysis 
revealed that there was a statistically significant interaction between treatment and 
deprivation period for ERβ (F(3,38)=3.762, p=0.014), but not ERα. ERβ mRNA 
expression was significantly decreased at 4,8, and 12 weeks post-OVX in the vehicle 
treated samples (Fig. 17B, black line, #). However, E2 significantly increased ERβ 
mRNA expression at 4 and 12 weeks post-OVX (Fig. 17B, gray line, *).  
  Next, we ovariectomized aged (18 month old) Fischer 344 female rats and 1 week 
later administered either E2, or an ERα (PPT) or ERβ (DPN) selective agonist. We then 
measured the primary, precursor, and mature miR expression levels for each of our 
previously identified E2 regulated miRNAs using qRT-PCR (Fig. 18). First, we analyzed 
the expression levels of the primary transcripts, which demonstrated that both PPT and 
DPN treatment significantly decreased the expression of pri-miR-7a, pri-miR-125a, pri-
miR-181a, and pri-miR-495 compared to either vehicle or E2 treated animals (Fig. 18A). 
These results were surprising given that no effect was observed with E2 treatment alone. 
Interestingly, let-7i primary transcript expression was the only miRNA to be significantly 
increased with DPN and PPT treatment (Fig. 18A). By contrast, PPT significantly 
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increased the expression of the precursor form of miR-181a (pre-miR-181a), but had no 
effect on the precursor forms for any of the other miRNAs (Fig. 18B). Similarly, DPN 
significantly increased the precursor form of miR-495 (pre-miR-495), but not any other 
precursor miRNA (Fig. 18B). Finally, DPN, but not PPT, mimicked the effects of E2 on 
the expression levels of mature let-7i, and miR-7a, which was consistent with our earlier 
observations after 1 week of E2 deprivation (Fig. 18C).  
The effects of PPT and DPN on miR-9 were particularly interesting. Our 
previously published observations, as well as replicated data herein, demonstrated that E2 
significantly increased both the guide (miR-9) and passenger (miR-9-3p) strands of 
mature miR-9 after 1 week of E2 deprivation in aged animals. However, both PPT and 
DPN significantly decreased the pri-miR-9 and pre-miR-9 forms of this miRNA (Fig. 
18D, E). Notably, E2 tended to increase pri-miR-9, and decrease pre-miR-9, but neither 
effect was statistically significant. Finally, E2, PPT, and DPN all significantly increased 
mature miR-9 and miR-9-3p, but DPN increased each to a greater degree (Fig. 18F, G). 
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Figure 16. Estrogen receptor isoform expression in the hypothalamus. 
A-B) Expression of ERα (A) and ERβ (B) mRNA in the hypothalamus 
analyzed by real time RT-PCR (N=6 treatment/age group).  
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Figure 17. ERβ regulates mature miRNA expression in the hypothalamus. 
A-G) Primary (A,D), precursor (B,E), and mature (C,F-G) miRNA expression in the 
hypothalamus of vehicle, E2, DPN, and PPT treated female rats 1 week post-OVX. Data 
is displayed as fold change as compared to 1 week vehicle treated animals. Statistical 
significance was analyzed using one-way ANOVA with Tukey’s post-hoc test.   
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Summary 
Our primary objective in these studies was to test the efficacy of acute E2 
treatment, administered at different time points following the complete loss (via OVX) of 
ovarian hormones, on miRNA expression in the aged female brain. The results from this 
study demonstrated several novel findings. First, E2 treatment altered mature miRNA 
expression in the brain of aged animals after 1 week of ovarian hormone deprivation, but 
this effect was lost following longer periods of hormone deprivation. These results are 
consistent with that of the Timing Hypothesis, which suggests that the efficacy of E2 
action changes with advanced age and length of time postmenopause. Second, our results 
showed that E2 treatment selectively altered the expression of the primary and precursor 
transcripts of these same miRNAs, however those expression levels often did not 
correspond to the levels of their mature miRNA counterparts. Our interpretation of these 
data is that E2 can act at multiple levels along the miRNA biosynthesis pathway, and that 
E2 perhaps plays a role in the stabilization of mature miRNAs. Third, we showed that 
aging alone (i.e. vehicle treatment) also had a significant effect on mature miRNA 
expression in many cases, and these are the first data to describe miRNA expression 
levels in the brains of animals at several time points of advanced age. Finally, using ER 
selective agonists we demonstrated that the effects of E2 on mature miRNA expression in 
the hypothalamus are likely mediated primarily through ERβ. Taken together these 
results extend our previous findings by suggesting a possible mechanism for the lack of 
therapeutic effectiveness for HT in post-menopausal women.  
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Our previous work showed that E2 differentially regulates the expression of 
mature miRNAs in the brains of young, compared with aged, female rats [190]. This 
current study extends those findings by focusing only on aged animals that were given E2 
replacement at varying times post-OVX. Consistent with our earlier findings, E2 
treatment significantly increased 5 out of 7 previously identified mature miRNAs after 
only a brief period of ovarian hormone deprivation (i.e. one week) in aged animals. It is 
important to note that these current studies examined mature miRNA expression only in 
the hypothalamus, whereas our previous findings were mostly derived from the 
hippocampus. Nevertheless, these data remained consistent with our earlier results in that 
there appears to be brain-region specific effects of E2 on miRNA expression. Notably, 
we observed no differences in mature miRNA expression between E2- and vehicle-
treated animals following longer periods of ovarian hormone deprivation (i.e. 4, 8, and 12 
weeks). These results are in-line with the concept of the Timing Hypothesis, which 
predicts a lack of E2 efficacy following longer periods of ovarian hormone deprivation. 
miRNAs are important regulators of mRNA translation and are predicted to impact the 
expression of more than 60% of all protein-coding genes [152]. The implication of these 
results suggests that a loss of E2-regulated miRNAs postmenopause could negatively 
impact multiple downstream target genes, although it remains unclear which specific 
downstream target genes these particular miRNAs regulate.  
Despite their critical role, little is known about the tissue-specific regulation of 
miRNA biosynthesis and processing. In general, global miRNA biogenesis follows a 
well-defined pathway beginning with the generation of a long primary transcript (pri-
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miR) and ending with a single-stranded 22 nt mature miRNA product [43,45,46,52,54]. 
There are several steps along this pathway that are potential points where unique tissue- 
and age-specific expression of individual miRNAs could occur. Estrogen receptors act 
primarily as transcription factors on various gene promoters, therefore, the most likely 
site of E2 regulation is at the transcriptional level of the primary miRNA form. Indeed, 
others have demonstrated that E2 regulates several pri-miRs through canonical estrogen 
response elements (EREs) in breast cancer cell models [117,121,193]. Therefore, we next 
measured the expression levels of the primary (pri-miR) and precursor (pre-miR) forms 
of our identified E2-regulated mature miRNAs at varying times post-OVX. Our 
prediction was that expression levels of these earlier transcripts would match that of the 
mature miRNA effector, however this was not what we observed. In fact, there was 
considerable discordance between the pri-, pre-, and mature forms for most of the 
miRNAs tested. The discordance observed could be the result of altered processing of 
these miRNAs. Post-transcriptional modifications to RNAs, including miRNAs, have 
been shown to be common and important regulatory mechanisms, which can either 
promote or inhibit their processing [181,184,185,194]. Additionally some of these 
modifications have been shown to be altered with aging [195]. These studies suggest that 
not only expression, but sequence changes to the miRNA should be analyzed to more 
completely understand their regulation and function. There is little known about the 
temporal regulation of miRNA biosynthetic events, but these results suggest that E2 
could regulate different steps along the pathway at different times. It also demonstrates a 
limitation of our studies in that each miRNA form was measured at just one snapshot in 
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time following E2 treatment (24 hours following the last injection). Nevertheless, the fact 
that E2 regulated all of the miRNAs forms at some time point indicates that E2 might 
also regulate some of the important key proteins involved in miRNA biogenesis and/or 
stabilization. 
Mature single-stranded miRNA molecules in association with an AGO protein 
comprise the two core components of the RNA-induced silencing complex [62]. The 
mature miRNA molecule is formed after the cytoplasmic RNase III enzyme dicer cleaves 
the pre-miR to form a small miRNA duplex structure [52]. Only one strand of this duplex 
(leading strand) associates with AGO; the other strand (passenger strand) remains free, 
either to bind to RNAs and other proteins or be degraded [56,57,58]. In contrast to that 
description of miRNA formation, our data showed that E2 treatment not only increased 
the expression of mature miR-9 in aged females, but it also increased the expression of 
the miR-9a passenger strand, miR-9-3p (current study, and [190]). Because both strands 
of the miR-9 duplex are derived after dicer processing of the same precursor molecule, 
these results provide strong evidence that E2 can regulate miRNA expression at the level 
of molecular stabilization. Therefore, to determine if E2 regulates key components of 
miRNA biogenesis or stabilization we examined their mRNA and protein levels in our 
ovarian hormone deprivation paradigm. We observed that E2 treatment significantly 
increased drosha and dicer mRNA at 8 weeks post-OVX, however these changes were 
not mirrored by changes in protein levels at that same time point. One possibility is that 
we missed the window of detection, given that we measured both mRNA and protein at 
only time point following E2 treatment (24 hours after the last injection). Moreover, the 
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levels of mRNA and protein for these enzymes do not necessarily reflect changes in 
enzyme activity. Importantly, the enzymatic activities are acutely sensitive to rapid 
changes in co-factor binding and posttranslational modifications [52,53,54,181,196], all 
of which are potential targets for E2 regulation. At this time, we are unaware of any 
enzymatic assay that has been developed for the detection of dicer or drosha activity 
either in cell line models or tissue, making this a very important future direction for 
research efforts. Overall, there were no significant changes due to age or treatment on the 
protein expression for any of the other key miRNA biogenesis or stabilization 
components tested. These results are consistent with our findings, and that of others, 
showing that E2 and age only regulate a very small subset of miRNAs [116,190]. 
Therefore, E2 regulation of a major protein component in the miRNA biogenesis 
pathway is unanticipated, as that would predict a broad impact on a much greater number 
of miRNAs.  
The results of the WHI studies prompted both basic and clinical scientists to 
reevaluate the role of E2 in the aging brain. Changes in the composition, number, or 
structure of estrogen receptors (ERα or ERβ) would be an obvious explanation for 
reduced E2 efficacy with age. Indeed, previously published studies have shown that both 
ERα and ERβ expression are altered with aging in specific nuclei of the hypothalamus, 
although the reported literature are somewhat contradictory with respect to ERβ 
[197,198,199]. Our data showed that there was a significant decrease in ERβ mRNA 
expression at 4, 8, and 12 weeks post-OVX (equivalent to 19, 20, and 21 months old, 
respectively) in both the vehicle and E2-treated animals. However, treatment with the 
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ERβ specific agonist DPN was equally effective as E2, and there were no changes 
observed in ERα expression, suggesting that decreased ER availability is not a primary 
factor for the lack of E2 efficacy in the aged female brain. However, one important 
consideration to take in to account when evaluating receptor expression is that there are 
multiple splice variants of ERβ. Our experiments were designed to detect the full-length 
wild-type ERβ, which would also be inclusive of all known ERβ splice variants. In 
particular, ERβ2 has lower E2 binding affinity, different transcriptional efficacy, 
increases with age, and was correlated with an increase in depressive behaviors in aged 
Sprague-Dawley female rats [14,200,201]. Therefore, the ERβ mRNA expression levels 
that we observed could also represent a large cohort of ERβ2, which would not respond 
to E2 as well as wild-type ERβ. Another important consideration is that proper ER 
signaling requires the successful recruitment of a variety of co-regulator proteins. We 
have previously demonstrated that the protein complexes associated with ERβ in the 
brain are altered by E2 in an age-dependent manner, despite no age-related changes in the 
expression of the cofactor proteins themselves [202]. These data indicate that altered ER 
and/or cofactor gene expression might not be good markers to assess the efficacy of E2 
signaling.  
Although the actions of E2 are mediated primarily through its two classical 
nuclear receptors, ERα and ERβ, recent evidence has emerged implicating E2 regulation 
of cell function through a variety of other intracellular signaling pathways, some of which 
are mediated by membrane-bound ER or G protein-coupled receptors. In these studies, 
we used a straightforward approach to try to identify whether the classical ERs were 
81 
 
 
mediating the E2-induced regulation of mature miRNA expression in the aged brains 
following a brief period (1 week) of ovarian hormone deprivation. To that end, we took 
advantage of the recent development of the specific ERα and ERβ agonists, PPT 
(propylpyrazole-triol) and DPN (diarylpropionitrile), respectively. These agonists have 
been shown to be highly selective for their respective form of the receptor when used at 
the doses we administered [203,204]. In general, our results indicated that the E2-induced 
regulation of mature miRNAs after one week of OVX was mediated primarily by ERβ. 
Interestingly, there were some instances, most notably at the primary (pri-miR) level, 
where PPT and DPN were equally efficacious and E2 had no apparent effect (see Fig. 
18). Previous studies have demonstrated that ERβ can act as a dominant negative to ERα 
and our results suggest that both receptors can separately mediate transcription of the 
primary transcripts, but they negate each other’s effects when activated in concert. An 
important future study will be to determine if PPT or DPN effects change following 
longer periods of ovarian hormone deprivation. Although we showed no effect of E2 at 
later time points, it is possible that each receptor alone would have time-specific effects, 
making these ER selective agonists a potentially useful therapeutic tool for 
postmenopausal women. 
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CHAPTER V 
THE EFFECT OF AGING ON MATURE MICRORNA EXPRESSION 
IN THE HYPOTHALAMUS OF OVARY INTACT RATS 
 
INTRODUCTION 
Advanced aging increases the risk for developing chronic neurological disorders 
such as dementia and Alzheimer’s disease. These risks could be the result of a 
progressive dysregulation of developmental expression patterns of key genes. miRNAs 
are critical for the development of the brain and have been shown to show altered 
expression patterns with advanced aging [71,83,84,108,109,111,112,113,123]. In 
addition, miRNA expression patterns mirror changes in both gene mRNA and protein 
expression patterns with advanced aging, suggesting that they are critical regulators of 
age-related processes.   
The previous chapters have shown alterations in the expression of miRNAs 
regulated by E2 with advanced aging. However, those animals had undergone removal of 
their ovaries and were then given an E2 treatment. It is possible that the age-related 
expression pattern of these miRNAs could be different if they had undergone removal of 
their ovaries. An understanding of the normal age-related expression changes of the 
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Figure 18. miRNA expression is altered with advanced aging in the hypothalamus of 
intact female rats. 
A-F) Real time RT-PCR analysis of miRNA expression in the hypothalamus of 18, 19, 20 
, and 21 month ovary intact female Fischer 344 rats (N=6/age group). One-way ANOVA 
with tukey’s post-hoc was performed for statistical analysis. 
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miRNAs could help to understand what other factors are important for regulating these 
miRNAs.  
Results 
 Fischer 344 female rats were obtained at 18 months of age and then allowed to 
age until 21 months of age. Animals were sacrificed at 18, 19, 20, and 21 months of age. 
The right side of the hypothalamus was isolated and processed for RNA isolation. Real 
time RT-PCR analysis of the mature miNRA expression of the seven identified miRNAs 
was performed. One-way ANOVA statistical analysis identified a significant effect of 
aging with all seven miRNAs. 5 of the 7 miRNAs (let-7i, miR-7a, miR-9, miR-9-3p, and 
miR-495) were significantly increased in expression at 20 and 21 months of age. Only 
miR-125a and miR-181a showed a decrease in expression. miR-125a was decreased at 19  
months of age, but then increased in expression at 20 and 21 months. miR-181a was 
significantly decreased at 19, 20, and 21 months of age. 
miR-9 and miR-9-3p are derived from the same precursor transcript and therefore 
are transcribed from the same gene. Usually, the lagging strand of the miRNA duplex 
(miR-9-3p) is degraded. Interestingly miR-9-3p expression was significantly increased 
with aging, while miR-9 was also increased but not to same extent. These data suggest 
that is there is differential strand selection occurring with aging. 
Summary 
The results herein have demonstrated that the previously identified seven 
miRNAs are significantly regulated with aging. These data are line with other previous 
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studies have demonstrated. The data also demonstrate, in the case of miR-9/miR-9-3p, 
there is an alteration in the selection of the lagging strand of the precursor miRNA with 
aging. Since the both the mature miRNA s are derived from the same primary and 
precursor miRNA transcripts, these data suggest a post-transcriptional mechanism. 
Currently it is not understood how the mature miRNA strand selection occurs, though 
modifications to miRNAs themselves is a possibility.  
Importantly these expression patterns are not what were seen the vehicle treated 
animals in the previous Chapter IV. These data preliminary suggest that ovariectomy 
greatly altered the expression pattern of the miRNAs. It is possible that these miRNAs 
could be regulated by another steroid hormone secreted by the ovaries, such as 
progesterone. Further study is required to understand what other regulatory factors are 
important for regulating the miRNAs. 
 
 
 
 
 
 
  
86 
 
 
CHAPTER VI  
17β-ESTRADIOL REGULATES THE EXPRESSION OF MIR-7 IN 
NEURONAL CELL LINES 
 
Introduction 
 The previous chapters have demonstrated E2 regulation of miRNAs in-
vivo. However, there are experimental limitations to what can be accomplished in-vivo to 
understand the precise E2 molecular mechanisms which are regulating miRNA 
expression. Therefore an in-vitro model is needed to be able to precisely manipulate the 
actions of E2 on miRNA expression. Previously studies on E2 regulation of miRNA 
expression have been performed in-vitro using breast and prostate cancer cell lines 
[116,117,121]; as of this writing there is no published work demonstrating the regulation 
of miRNAs in a neuronal cell line.  
 Previously, I have demonstrated the regulation of miRNAs by E2 in both 
the hippocampus and the hypothalamus. Therefore, in this chapter I will use two different 
neuronal cell lines derived from hippocampus and the PVN of the hypothalamus brain 
regions to examine the regulation of miRNA expression by E2. The IVB cell line is 
derived from the PVN of the rat hypothalamus and expresses only ERβ [205]. The HT22 
87 
 
 
 
cell line is a sub-line cloned from the HT4 cell line derived from the mouse 
hippocampus[206]. The HT22 cells do not express the either estrogen receptor and 
therefore provide a unique opportunity to study regulation of miRNA expression of 
estrogen receptors individually by ectopic expression. miR-7 was regulated by E2 in both 
the hippocampus and hypothalamus; therefore it was used to determine the effect of E2 
on  miRNA expression in-vitro. The results herein demonstrate that E2 is able to regulate 
miRNA expression in the both the IVB and HT22 neuronal cell lines, however that 
identified miRNAs are expressed at lower levels compared to what was seen in-vivo. 
Results 
Estradiol regulates miR-7 expression in the PVN derived cell line IVB through ERβ 
The IVB cells were maintained in phenol-free media with charcoal dextran treated 
fetal bovine serum (FBS) to ensure that there were no estrogens in the media. The cells 
were then treated with 10nM E2 overnight (16 hours). To determine if the action of E2 
was indeed through the estrogen receptor the cells were also treated with an estrogen 
receptor antagonist, ICI-182,780, alone and in combination with E2. RNA was isolated 
from the cells after the treatment period and miR-7 expression was analyzed by qRT-
PCR. One-way ANOVA analysis demonstrated that there was an effect of treatment on 
miR-7 expression. Post-hoc pair wise comparisons show that miR-7 expression was 
significantly increased with E2 treatment as compared to vehicle treated cells (Fig. 20). 
Interestingly, the antagonist ICI-182,780 also significantly increased miR-7 expression 
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and did not inhibit E2 induced miR-7 expression when administered in combination (Fig. 
20).     
The IVB cells express ERβ only; therefore the effect of E2 must be through that 
receptor. However to conclusively determine that ERβ regulates miR-7 expression, IVB 
cells were treated with 100nM 5α-androstane-3β, 17β-diol (3β-diol); a high affinity 
agonist for ERβ. miR-7 expression was also significantly increased in the IVB cells in 
response to treatment with 3β-diol (Fig. 21).  
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Figure 19. miR-7 expression in IVB cells after treatment with 17β-estradiol. 
IVB cells were maintained DMEM phenol-free media with 10% charocoal dextran treate 
FBS 24 hours prior to treatment. Cells were treated with 10nM E2, 100nM ICI-182,780, 
or E2+ICI for 16 hours (N=3 repeated experiments). RNA was isolated from cells and 
miR-7 expression was analyzed  using real time RT-PCR. Data are displayed at fold 
change compared to vehicle treated cells. One-way ANOVA was performed with 
Tukey’s post-hoc test. 
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Figure 20. ERβ regulates miR-7 expression in IVB cells. 
IVB cells were maintained DMEM phenol-free media with 10% charocoal dextran treate 
FBS 24 hours prior to treatment. Cells were treated with 100nM 3β-diol for 16 hours 
(N=3 repeated experiments). RNA was isolated from cells and miR-7 expression was 
analyzed using real time RT-PCR. Data are displayed at fold change compared to vehicle 
treated cells. * indicates p-value < 0.05 (student’s t-test). 
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Estradiol does not regulate miR-7 expression in hippocampal cell line HT22 
Estradiol was able to regulate miR-7 expression in the IVB cell line; however we 
also wanted to see if this effect would also be seen in the hippocampal cell line HT22. 
HT22 cells were maintained in phenol-free media with dextran charcoal treated FBS. 
Cells were transfected with either pcDNA vector or a vector containing rat ERβ. 24 hours 
later the cells were treated with either E2, an estrogen receptor antagonist tamoxifen 
(OHT), or both in combination. Analysis of miR-7 expression by qRT-PCR showed that 
there was no effect of treatment with either pcDNA or ERβ transfection (Fig. 22). 
However, ERβ transfection alone significantly decreased miR-7 expression. In order to 
see if the effect of ERβ transfection was unique to miR-7 or was actively repressing other 
miRNAs, miR-9 expression was analyzed by qRT-PCR. Expression of miR-9 was not 
repressed by ERβ transfection (Fig. 22). Estradiol increased miR-9 expression modestly 
in ERβ transfected cells in comparison to pcDNA transfected cells treated with E2 (Fig. 
22). However, OHT treatment also increased miR-9 expression in both pcDNA and ERβ 
transfected cells (Fig. 22). 
The previous results are the first to demonstrate E2 regulation of miRNA 
expression in a neuronal cell line. The effects of E2 on miR-7 and miR-9 are modest; 
therefore we wanted to determine if we could see an effect of E2 on a well-established 
miRNA, miR-21.  miR-21 has been shown to be regulated by E2 in different cancer cell 
lines [116,117]. HT22 cells were transfected with pcDNA, ERα, or ERβ for 24 hours and 
then treated with 10nM E2 for 16 hours. Expression of miR-21 was significantly 
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increased with E2 in ERα transfected cells, but not in pcDNA and ERβ transfected cells 
(Fig. 23). 
miR-7 expression is lower in-vitro than in-vivo 
The effects of E2 on miR-7 expression in in-vitro have been modest in 
comparison to in-vivo. One possible explanation is that since these neuronal cells are 
immortalized they may not express miR-7 at the same level as a neuron would. To 
determine if was true, miR-7 expression was compared across ventral hippocampus, 
dorsal hippocampus, hypothalamus, HT-22 cells, and IVB cells. miR-7 expression in 
both the HT22 and IVB cells were much more lowly expressed than in the ventral 
hippocampus, dorsal hippocampus, and hypothalamus (Fig. 24).  
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Figure 21. ERβ transfection in to HT22 cells represses miR-7a expression. 
HT22 cells were transfected with either pcDNA (control) or rat ERβ1 plasmid for 24 
hours and then treated with vehicle, 10nM E2, 100nM OHT, or E2+OHT for 16 hours 
(N=3 repeated experiments). miR-7a (A) and miR-9 (B) expression are displayed as fold 
change as compared to pcDNA vehicle cells. 
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Figure 22. miR-21 is regulated by E2 in HT22 cells transfected with the estrogen 
receptors. 
HT22 cells were transfected with pcDNA, ERα, or ERβ1 for 12 hours and then treated with either 
vehicle or 10nM E2 for 16 hours (N=3 repeated experiements). miR-21 expression is displayed as 
fold change compared to pcDNA vehicle samples. 
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Summary 
 
Figure 23.  Relative expression of miR-7 across brain regions and neuronal cell 
lines. 
Fold change in miR-7 expression in 18 month old OVX vehicle treated ventral 
hippocampus (VHipp), dorsal hippocampus (DHipp),  hypothalamus, hippocampal 
neuronal cell line HT22, and PVN derived cell line IVB.  
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 In the present chapter I have demonstrated that E2 can increase miR-7 
expression in the PVN derived cell line IVB, but not in the HT22 cell line. Interestingly, 
miR-7 expression was greatly reduced upon transfection of ERβ in to the HT22 cell line; 
this effect of ERβ transfection was not observed on miR-9 or miR-21 expression. miR-7 
was also shown to be much more lowly expressed in the both the IVB and HT22 cell 
lines as compared to hippocampal and hypothalamus tissue.  
It is possible that the immortalization process has induced some unknown factors 
to repress miR-7 expression. Detection of the primary and precursor transcripts of miR-7 
was attempted, but they were not able be detected; these observations further suggest a 
repression of the transcription of miR-7 in both the IVB and HT22 cell lines. Taken 
together these data suggest that an in-vitro approach using neuronal cell lines is not 
recommended as the relative levels of miR-7 are much lower than what is seen in-vivo. 
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CHAPTER VII  
DISCUSSION 
 
Summary of Key Findings 
The WHI clinical studies identified that HT was no longer beneficial for 
ameliorating the risks of chronic cognitive disorders in women who were more than 10 
years post-menopause. I hypothesized that this loss of E2 effectiveness could be due to 
age related alterations in the E2 regulation of miRNAs, which would ultimately result in 
altered expression of protein coding genes. In support of my hypothesis I have identified 
a sub-set of miRNAs (let-7i, miR-7a, miR-9, miR-9-3p, miR-125a, miR-181a, and miR-
495) that are regulated by E2 in an age dependent manner in the ventral hippocampus. 
These same miRNAs are differentially regulated by E2 in other anatomically connected 
brain regions (dHipp, PVN, and CeA). While aging is key component in altering E2 
regulation of miRNA expression, I have also demonstrated that extended hormone 
deprivation results in the loss of E2 regulation of miRNA expression. Furthermore, I used 
selective estrogen receptor agonists to determine that ERβ is primarily responsible for 
mediating the effects of E2 on miRNA expression.  I have also analyzed the expression 
the primary and precursor transcript of these identified E2-regulated miRNAs and
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determined that E2 can alter the transcription of the primary miRNA transcript. The 
results presented suggest that E2 regulation of miRNAs in brain could play a key role in 
the loss of effectiveness of HT in post-menopausal women. 
The Impact of miRNAs for Women’s Health 
The modern age has increased the life span of humans greatly and as such women 
are living almost a third of their lives without circulating E2. The WHI studies were 
successful in determining that generally women who were in the peri-menopausal time 
period could be see a beneficial effect of HT. However there is no clinical test for 
patients to determine whether they may actually see any benefit from HT. miRNAs are 
uniquely positioned to be excellent biomarkers to judge the effectiveness of HT. For 
instance, miRNAs have been shown to be circulating in the blood of human patients and 
animals, which allow them to be assayed using a minimally invasive procedure [113]. 
Previous studies have also demonstrated that circulating miRNAs are actively secreted in 
the bloodstream and can act as signaling molecules [207]. It is possible that the seven 
miRNAs that I have identified could also be detected in the bloodstream or CSF (cerebral 
spinal fluid) of human patients. Specifically, members of the let-7 family of miRNAs 
have identified in the CSF of AD patients [207]. Therefore, an increased circulating level 
of let-7i in the CSF following HT might be a good indication that HT is not a good 
treatment option for a patient, since I demonstrated that E2 regulation of let-7i is age 
dependent.  
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Biomarkers are a good way for identifying if a woman can use HT without ill 
effect, however those women for which HT is not option still need a therapy to relieve 
the negative symptoms associated with menopause and decrease their risk for chronic 
diseases. Targeting specific miRNAs can be used as a therapeutic agent to repress 
pathogenic pathways in the brain. Inhibition of specific miRNAs, by the use of antagonist 
miRNAs (antagomiRs), would inhibit the effects of those miRNAs. Alternatively, 
overexpressing a miRNA identified to be neuroprotective might also help in reducing a 
post-menopausal women’s risk of developing chronic neurological disorders. Taken 
together, the data presented herein, along with that of others, strongly suggest that 
miRNAs have clear clinical applications for the assessment and advancement of women’s 
health. 
Estradiol regulation of miRNA expression 
The microarray for miRNAs in the ventral hippocampus detected 421 miRNAs 
out of 723 miRNAs on the array. Of the 423 miRNAs detected, 133 miRNAs displayed 
moderate to high expression. The seven miRNAs that were chosen were among those that 
were highly expressed. Yet there were 288 miRNAs that displayed low expression. While 
I did not focus on these miRNAs for further consideration, these miRNAs still may play a 
crucial role in neurobiology of the brain. Indeed there have been two studies that have 
demonstrated that altered expression of a miRNA determined from total RNA isolated 
does not necessary reflect a functional impact [208]. Low expression of a miRNA has 
been shown to correlate to increased occupancy to the RISC complex, whereas high 
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expression of miRNA correlates to a low occupancy [208]. These studies suggest that in 
order to gain insight to whether a miRNA is truly functional, analysis of its occupancy in 
the RISC complex is crucial since it’s through the RISC complex that miRNA exerts its 
actions. 
Brain region specific miRNA expression 
It is very possible that our initial microarray study, which was performed on 
ventral hippocampus samples, biased our focus on a particular group of miRNAs, since 
miRNAs have a brain region specific distribution. E2 probably regulates more and/or 
different miRNAs in other brain regions. Furthermore, our study did not separate out 
specific brain cell types, such as glia versus neurons, which means we cannot say for 
certain where E2 is acting to regulate these particular miRNAs. However, previous 
studies using in-situ hybridization and specific cell type analysis on miRNA expression in 
the brain showed that the let-7 family members, miR-9, miR-7a, and miR-125a are all 
specific to neurons [94]. Therefore, the altered regulation of miRNA expression by E2 is 
most likely impacting neuronal processes. 
Non-validated miRNAs from the microarray 
My studies focused on seven miRNAs that were regulated by E2 in an age-
dependent manner. Yet, the microarray identified 34 miRNAs that were regulated by E2 
independent of age. Some of these miRNAs, such as miR-21, were already identified as 
E2 regulated miRNAs; however those previous studies were all done in breast cancer cell 
lines [116,117,121]. If E2 can regulate the same miRNA in multiple different tissues, it 
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may suggest that the miRNA may have the same gene target across all the tissues. For 
instance, miR-29a, identified in our study as being E2 regulated, has also been shown to 
be a sexually dimorphic miRNA; suggesting that its regulation by E2 may be key in 
regulating sex specific functions. Further, miR-26a is a miRNA that was previously 
identified to be localized to the dendrites of neurons and is also regulated by E2. This 
observation suggests that E2 might regulate synaptic plasticity through miR-26a. These 
miRNAs and others await further exploration in their roles in E2 regulation of brain 
function. 
Transcriptional regulation of miRNA expression by E2  
E2 has previously been shown to regulate miRNAs in a transcriptional dependent 
process [121]. These studies demonstrated that E2 was able regulate both the pri- and 
pre-miRNA expression correlating with that of the mature miRNA expression level. My 
analysis of the primary and precursor transcript expression levels demonstrated that E2 
can regulate the transcription of miRNAs, however the precursor miRNAs were generally 
unchanged across the board following E2 treatment. The discrepancy between the three 
levels of miRNAs could be due the enzymatic activity of the miRNA processing 
enzymes. The pre-miRNA could be efficiently cleaved to the mature miRNA form 
thereby not allowing for the accumulation that would detected by qRT-PCR. 
Interestingly, the mature miR-181a was increased at 1 week post OVX by E2, yet there 
was no regulation of the primary transcript at this time point. These results suggest that 
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E2 may be able to able to regulate the mature miRNA expression through other non-
transcriptional mechanisms. 
Non-transcriptional effects of E2 on miRNA biogenesis  
The discrepancy between miR-181a mature and primary transcript levels could be 
explained by E2 preventing the degradation of the miRNA. There are multiple factors 
that can regulate the stability of the miRNA transcript. miRNAs associated with AGO 
have been shown to have very long half-lives, on the order of days to weeks, presumably 
due to protection from exoribonuclease degradation enzymes [209]. However, the 
majority of these studies have been done in immortalized cells, where in-vivo analysis 
has shown that some miRNAs can be rapidly degraded [101]. The precise mechanism of 
how miRNAs are unloaded from the RISC complex and then degraded is not completely 
understood. The exonuclease, XRN2, is one known enzyme responsible for degrading 
mature miRNAs in animals . How XRN2 gains access to the mature miRNA is not yet 
clear, however it has been shown that the target mRNA binding induces rapid 
degradation of the miRNA. miRNAs can also be post-transcriptionally modified, the 
results of which can regulate their stability and loading on to the RISC complex. 
Uridilyation of miRNAs is another mechanism that has been shown to target miRNAs for 
degradation [181]. However, different post-transcriptional modifications can have 
opposing effects on miRNA stability. Methylation, on the one hand, stabilizes miRNA 
expression by preventing uridylation of the miRNA [210]. Additionally, previous studies 
have shown that the abundance of mRNA transcripts helps to determine the stability of a 
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miRNA by binding to it when in the RISC complex, thereby preventing its degradation 
[182]. Therefore, regulation of miR-181a could be indirectly due to E2 increasing the 
transcription of a specific mRNA target gene of miR-181a, resulting in retention of miR-
181 in the RISC complex and consequent prevention of its degradation (Fig. 24).  
The Estrogen Receptors in the aging female brain 
The estrogen receptors are the primary mediators of all of E2 actions within the 
cell. I had determined that four of these miRNAs (let-7i, miR-7a, miR-9, and miR-9-3p) 
were regulated by ERβ in the hypothalamus, although ERα was able to also regulate miR-
9 and miR-9-3p.  
 
 
104 
 
 
  
 
 
 
 
 
 
 
Figure 24. mRNA transcript abundance prevents miRNA degradation 
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Since these miRNAs were not regulated by E2 at 4, 8, and 12 weeks post-OVX, it 
suggests that the estrogen receptors themselves might be altered during this time period. 
Therefore, I analyzed the mRNA expression of both ERα and ERβ, of which only ERβ 
expression significantly increased at 8 and 12 weeks post OVX. However, neither 
receptor was regulated by E2 treatment, but rather was regulated by age alone. Previous 
studies of estrogen receptor expression in the brain of middle age rats have shown mixed 
results of the effect of E2. One study by Yamaguchi et al. demonstrated that ERβ was 
decreased in several nuclei of the hypothalamus with E2 [211]. Another study by 
Chakraborty et al. showed that there was no effect of E2 on ERβ expression in the 
hypothalamus; however, they did show that ERβ expression was decreased in specific 
nuclei of the hypothalamus as a result of aging [198].  ERα expression has been shown be 
increased with aging in the hypothalamus [197]; however I did not see any change in the 
mRNA expression of ERα.  
Another important consideration is that estrogen receptors do not act alone, and 
require assistance by a group of co-regulatory proteins. A study by Mott et al. 
demonstrated that ERβ’s interaction with co-regulatory proteins is altered with aging in 
the hippocampus [202]. In particular, Mott et al. identified HNRNP H as differentially 
associated with ERβwith aging. The HNRNP proteins, including HNRNP H, have been 
previously demonstrated to be key regulators of RNA processing as well as microRNA 
processing. The data from this study suggests that ERβ may alter miRNA expression by 
regulating the processing of miRNAs by interacting with HNRNP H. Additionally, the 
study found that altered interactions with these proteins could affect ERβ transcriptional 
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effects. For example gelsolin, which was increased in its association with ERβ in 3 month 
old animals with E2 but not in 18 month old animals, inhibited ERβ’s  ability to increase 
transcription of an AP-1 luciferase reporter. The inhibition was relieved when gelsolin 
was knocked down by siRNA. These data suggest that co-regulatory associations can be 
altered with aged which can change how ERβ is able to regulate transcription.  
Age dependent alterations in miRNA expression 
Aging not only altered the regulation of these miRNAs by E2 but also altered 
their basal expression alone. Previous studies have also shown that miRNAs are altered 
with aging in the brain and that their expression pattern is often a reversal or extension of 
the developmental period [90,111,114]. These data suggest that there are other 
developmental factors that become dysregulated with aging resulting in the altered 
miRNA expression pattern. Some of the miRNAs I have identified in this study, such as 
let-7i and miR-9, are known to be important for neurodevelopment. For example, miR-9 
has been previously been shown to be regulated at the transcriptional level by REST, a 
transcription factor key for suppressing neuronal genes in non-neuronal cells [150]. 
Similarly, the fragile X mental retardation (FMRP) is a key protein in neurodevelopment 
and its mutation results in mental retardation. Dicer can interact with FMRP and regulates 
the processing of pre-miR-9 cleavage to the mature miR-9, thereby altering miR-9 
expression [212]. It is possible that both of these neurodevelopmental proteins, REST and 
FMRP are altered with aging and they also may interact with, directly or indirectly, ERβ 
to regulate miRNA expression. Identification of these other factors, developmental and 
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non-developmental, are critical for understanding how aging is altering the expression of 
these miRNAs. 
MicroRNA Cellular Function 
The main effect that miRNAs have on a cell is to repress the translation of protein 
coding genes by binding to the 3’ UTR. I used three different miRNA target gene 
prediction computer algorithms to identify potential candidates in order to understand the 
downstream effects of the miRNAs I identified. Out of the four likely gene targets 
identified, SIRT1 (sirtuin 1) was the only one shown to have decreased mRNA 
expression correlating with my observed increases in miRNA expression. It is important 
to note that I did not measure the protein levels of SIRT1 to see if they correspond to the 
mRNA expression. However, a previous study using 3’UTR luciferase reporter constructs 
demonstrated that SIRT1 is a genuine target for miR-9, increasing the likelihood that 
SIRT1 is being regulated an E2 regulated miRNA [173].  
There are hundreds of possible gene targets for each miRNA due the fact that base 
pairing requirements are very loose, which makes target prediction algorithms somewhat 
unreliable since they are solely based on identifying complementary sequences between 
the miRNA and mRNA. There are multiple other factors besides the sequence that can 
affect targeting that can impact miRNA binding to a particular site, such as the secondary 
RNA structure of the 3’ UTR. Additionally, RNA binding proteins (RBP) not associated 
with the RISC complex can either promote or inhibit miRNA binding to an mRNA [174]. 
The precise mechanism of how a miRNA “chooses” a gene target is a key knowledge gap 
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that needs to examined if we are too be able understand the ultimate physiologically 
impacts of miRNAs. It is important to note, however, that there is a growing body of 
evidence suggesting that miRNAs are pleiotropic and can alter genes in a number of ways 
besides translational repression. 
Non-canonical Functions of miRNAs 
One of the first non-canonical functions discovered for miRNAs was the 
translational enhancement of ribosomal mRNAs by miR-10a [213]. The mechanism by 
which miR-10a enhanced the translation of these mRNAs was by binding to the 5’ UTR 
of the transcript, which would result in the recruitment of ribosomal components [213]. 
Since that publication, miRNA binding to the 5’UTR has also been demonstrated for 
miR-196b and miR-103a-3p [214,215]. These results underscore the importance of the 
location at which the miRNA binds on the transcript.  
miRNA binding to an mRNA transcript was originally thought to occur only in 
the cytoplasm, and this is where the majority of studies have focused their attention. 
However there is recent evidence that miRNAs can be localized to the nucleus. The first 
study to demonstrate this showed that miRNAs could be localized to the nucleus based on 
the presence of a nuclear import sequence [216]. Additionally, argonaute proteins can 
also be localized to the nucleus where they are bound to miRNAs [217,218]. One of the 
proposed functions of nuclear miRNAs is to regulate gene transcription. For example, let-
7i has been shown to bind to the TATA box promoter of interleukin 2, recruit RNA Pol 
II, and increase its transcription in CD4+ T lymphocytes [219]. Regulation of 
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transcription by miRNAs has also been shown to involve chromatin modifications via 
interactions with other non-coding RNAs, such as long non-coding RNAs (lncRNAs) 
[220,221].  
Limitations of the Study 
The experiments within this study have conclusively demonstrated that there is an 
age-dependency to E2 regulation of mature miRNA expression in the brain, and that 
ovarian hormone deprivation in aged female rats induces loss of E2 regulation of these 
same miRNAs. However, from these data it is not yet certain how E2 is regulating 
miRNA expression. The expression of the primary miRNA transcript sometimes 
correlates with mature miRNA, however there was not an observed correlative change in 
the precursor miRNA transcript for the majority of miRNAs tested. Additionally, E2 
regulated miR-181a expression only at the mature miRNA level, which suggests a non-
transcriptional mechanism for E2 action. The data obtained from these experiments were 
a snapshot of miRNA expression, obtained 24 hours after the last E2 injection was given. 
Therefore it is possible that any transcriptional effect of E2 could have occurred before 
24 hours. Likewise, the precursor miRNA expression could have been processed well 
before the animals were sacrificed. Importantly, E2 has been shown to have rapid effects 
on neurons which can occur within minutes of treatment. The treatment paradigm used in 
the present studies did not allow for an understanding of the dynamics of miRNA 
expression, which can occur within minutes to hours of E2 treatment. 
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The method to analyze miRNA expression in the study was real time RT-qPCR; 
for which I used total RNA isolated from specific brain regions. The brain is composed 
multiple cell types besides neurons, which the total RNA isolation would be pooling the 
transcriptome from all these cells. While previous studies have shown some of the 
miRNAs I identified to be restricted to a specific a cell type (i.e. miR-7 and miR-9 are 
expressed only in neurons), there is still not much known about cell type specific miRNA 
expression in the brain. The functional significance of these miRNAs is therefore difficult 
to predict since the gene targets of a given miRNA depend on the cell type. Additionally, 
miRNAs can localize to specific areas of cell, which can alter function.  The function of 
miRNAs is also dependent on other interacting proteins. For instance, studies have 
demonstrated that not all highly expressed miRNAs are associated with the RISC 
complex. Determination of the mechanisms governing and the roles of the identified 
miRNAs require more selective measurements and is an area for future research. 
Future Studies 
The results of the present study have laid a foundation upon which future 
experiments can be based in order to determine the precise regulatory mechanism used by 
E2 to alter miRNA expression and the ultimate function of these miRNAs. To this end, 
the treatment paradigm should include time points that are hours (1, 4, and 8 hours) after 
the last injection to determine when E2 is regulating miRNA expression.   
Future experiments should also attempt to replicate the ovarian deprivation 
paradigm in younger (3 month) animals to determine if the effect of the deprivation is 
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independent of the age of the animal. Importantly, a group of animals that did not 
undergo OVX surgery are also needed to determine the effect aging coincident with 
naturally progressing reproductive senescence on miRNA expression.  
The identification of specific miRNAs regulated by E2 in the brain allows for 
more in depth analysis of their regulation. To this end, cell specific expression and 
cellular localization should be assayed for the identified seven miRNAs by the use of in-
situ hybridization. Concurrently, RNA-immunoprecipitations (RIP) should be performed 
to assay for changes miRNA association with the RISC complex with aging and E2 
treatment. 
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CHAPTER VIII  
MATERIALS AND METHODS 
 
Ethics Statement 
All animal protocols were approved by the Institutional Animal Care and Use 
Committee at Loyola University Chicago, IACUC approval #2009018. Surgeries were 
performed under vaporized isoflurane anesthesia. Post-operation, animals were singly 
housed and provided with acetaminophen analgesic (122.7 mg/kg) in tap water for 3 
days. All measures were taken to minimize pain and suffering. 
Animals 
Female Fischer 344 rats (N=20) were obtained from the National Institutes of 
Aging (NIA) colony (Taconic) at 3 and 18 months of age for the experiments in Chapter 
III. Female Fischer 344 rats were obtained from the National Institutes of Aging (NIA) 
colony (Charles River Laboratories, Wilmington, MA) at 18 months (N = 59) of age for 
the experiments in Chapter IV. The animals were allowed to acclimate to the housing 
facility for 7 days after arrival.  Animals were housed two per cage and were allowed free 
access to food and water.  
Surgery 
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One week after arrival, animals were deeply anesthetized with vaporized 
isoflurane and bilaterally ovariectomized (OVX). Briefly, the ovary and distal end of the 
uterine horn were pulled from the body cavity through a 1 cm incision made through the 
skin and body wall. The uterine horn was clamped with a hemostat and ligated proximal 
to the clamp. The entire ovary and distal uterine horn were then removed. Animals were 
singly housed and provided with acetaminophen analgesic (122.7 mg/kg) in their water 
for 3 days postoperative. During this time, animals were weighed once/day and their 
water intake measured. Following 3 days of analgesia the animals were double-housed 
with their previous cage mate for the duration of the experiment. 
Treatment 
Seven days following OVX animals in each age group were given a subcutaneous 
injection of either safflower oil (vehicle) (N=10/age group) or 2.5μg 17β-estradiol (E2, 
N=10/age group) dissolved in safflower oil once/day for 3 days in Chapter III 
experiments. In Chapter IV experiments, following OVX animals recovered for 1, 4, 8, or 
12 weeks (N=11-12/age group). After the designated recovery time the animals were 
given a subcutaneous injection of either safflower oil (vehicle) (N=5-6/age group) or 2.5 
μg/kg 17β-estradiol (E2, N=6/age group) dissolved in safflower oil once/day for 3 days. 
We measured the E2 concentrations in both the E2 and vehicle treated animals by ELSIA 
(Enzo Life Sciences) after sacrifice. The animals were anesthetized and sacrificed by 
rapid decapitation 24 hours following the last E2 injection. Trunk blood was collected on 
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ice into heparinized 10 ml round bottom tubes, centrifuged at 4000 RPM for 8 min., and 
plasma stored at -20°C until further processing.   
Experiments in Chapter III had the rat brains quickly removed, sagitally sectioned 
into left and right hemispheres, and the hippocampus was microdissected from the left 
side of the brain and then further separated into the ventral and dorsal sub-divisions. The 
ventral and dorsal hippocampi were placed in separate microcentrifuge tubes containing 
QIAzol lysis reagent (Qiagen) reagent for subsequent homogenization and RNA 
extraction. The right side of the brain was rapidly frozen in 2-methylbutane, sectioned at 
200 µm on a freezing microtome, and the paraventricular nucleus (PVN, -1.40 to -2.12 
mm relative to bregma), central amygdala (CeA, -2.12 to -2.80 mm relative to bregma), 
ventral hippocampus (vHIPP, 4.30 to 6.04 mm relative to bregma), and dorsal 
hippocampus (dHIPP, -2.30 to 4.16 mm relative to bregma) were microdissected using a 
Palkovit’s brain punch tool (0.75 mm, Stoelting, Inc., Wood Dale, IL).  
In Chapter IV the brains were quickly removed, sagittal sectioned on ice into left 
and right hemispheres, and the whole hypothalamus was microdissected from the right 
side of the brain. The hypothalami were placed in separate microcentrifuge tubes 
containing QIAzol lysis reagent (Qiagen, Inc., Germantown, MD) reagent for subsequent 
homogenization and RNA extraction. The left side of the brain was rapidly frozen in 2-
methylbutane, sectioned at 200 µm on a freezing microtome, and the whole 
hypothalamus (-0.26 to -4.52 relative of bregma), were microdissected using a Palkovit’s 
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brain punch tool (1.0 mm, Stoelting, Inc., Wood Dale, IL). Tissue punches were placed in 
a microcentrifuge tube on dry ice and stored at -80°C.  
17β-estradiol plasma concentrations 
The plasma samples first underwent a liquid-liquid extraction using diethyl ether. 
Briefly, 1.0mL of diethyl ether was added to 200ul of plasma sample in a microfuge tube 
and mixed (vortex) for 2 minutes. Organic phase was transferred to a glass tube 
containing 1.0mL of H2O and mixed (vortex) for 2 minutes. Phases were allowed to 
separate for 2 minutes. Organic phase was transferred to clean glass tube and dried using 
nitrogen gas. Samples were reconstituted using 17β-Estradiol high sensitivity ELISA kit 
(Enzo Life Sciences, #ADI-901-174) sample buffer. The kit protocol was then followed. 
ELISA plates were read on BioTek Synergy HT plate reader. The circulating plasma E2 
concentrations of in the E2 and vehicle animals were 56.68 (+/- 20.29) and 36.10 (+/- 
9.70) pg/mL respectively (Figure 1B); these E2 levels are consistent with physiological 
levels observed during late diestrous/early proestrous [222]. The intra- and inter-assay 
%CV was 4.23 and 6.85 respectively.  
Cell Culture 
IVB cells were generously donated from Dr. Kasckow. Both IVB and HT22 cells 
were maintained in DMEM with high glucose and L-glutamine with 10% FBS. Cells 
were seeded in to six well plates at 100,000 cells/well in DMEM phenol free media with 
charcoal dextran treated FBS. IVB cells were treated with vehicle (ethanol), 10nM E2, 
100nM ICI-182,780, or E2+ICI for 16 hours.  HT-22 cells were transfected with either 
1.0µg pcDNA, rat ERβ1, or ERα with X-tremeGENE 9 DNA transfection reagent 
116 
 
 
(Roche). 24 hours after transfection, cells were then treated with vehicle (ethanol), 10nM 
E2, 100nM OHT, or E2+OHT for 16 hours. 
RNA isolation 
Total RNA was isolated from the whole right hypothalamus by the miRNeasy 
Mini Kit (Qiagen, Inc., Germantown, MD). All RNA samples were analyzed for quality 
by Nanodrop spectrophotometry and visualization of the RNA on 1.5% agarose gel.  
miRNA microarray processing and analysis  
5.0 μg of total RNA from the left side ventral hippocampus in each treatment (N = 
10) and age group (N = 10) was sent to LC sciences for rat miRNA microarray 
processing (miRBase 18 probe content). Multiple redundant regions were included in 
each chip and each region comprised a miRNA probe region listed from Sanger miRBase 
Release 18.0. Multiple controls were also included in each chip to control for quality of 
chip production, sample labeling and assay condition. Analysis of the microarray data 
was initially performed by LC sciences and further validated in our hands. The raw data 
from the microarray was normalized using quantile normalization and the false discovery 
rate was set at 5%, which is considered highly stringent. miRNAs that were statistically 
significant between age and treatment group were validated in the ipsi- and contra-lateral 
sides of the brain using qRT-PCR. We also analyzed each of the normalization genes for 
evidence of E2 regulation and samples were normalized to housekeeping genes that were 
not significantly altered by E2 or age (i.e. RNU5G).  
Precursor and mature miRNA cDNA synthesis 
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To assay for mature miRNA expression, 1.0 μg of total RNA was used to reverse 
transcribe miRNA using NCode™ VILO™ miRNA cDNA synthesis kit (Life 
Technologies, Carlsbad, CA). To assay for the primary and  precursor miRNA, we 
utilized a miRNA specific reverse transcription method described previously [223]. 
Briefly, 2.0 µg of total RNA was added to 1.5 μL of primer cocktail containing 10 μM of 
antisense primers (Table 1). The reaction mixture was incubated at 80°C for 5 minutes, 
60°C for 5 minutes, and then finally allowed to cool to room temperature. Reagents from 
the ThermoScript™ RT-PCR System (Life Technologies, Carlsbad, CA) were then added 
for a final volume of 20 μL. The reactions were incubated at 60°C for 45 minutes and 
then 85°C for 5 minutes. 1.0 μL of RNase H was added to each reaction and then 
incubated at 37°C for 20 minutes. 
mRNA cDNA synthesis  
2.0 μg of total RNA was reverse transcribed using the High Capacity cDNA 
Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA).   
Quantitative Real-Time PCR 
miRNA and mRNA qRT-PCR was performed with Fast Start Universal SYBR 
Green Master Mix (Roche-Genentech, San Francisco, CA) on an Eppendorf Realplex4. 
Forward primers for specific miRNAs were designed as described in the Ncode™ 
miRNA First-Strand cDNA synthesis kit handbook (Life Technologies, Carlsbad, CA) 
and using miRBase 18 as a sequence reference. The small RNA, RNU5G, was used as a 
loading control and to normalize the data for analysis. The following program was used: 
1) 95°C for 10 minutes, 2) 95°C for 20 seconds, 3) 59°C for 20 seconds, 4) 72°C for 10 
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sec, and melting curve analysis. miRNA expression was analyzed using the ∆∆Ct method 
as described previously [224].   
Western Blots 
Protein lysate from hypothalamus tissue punches were isolated using T-PER 
reagent (Thermo Scientific). Briefly, tissue punches were homogenized  in 500μl of T-
PER reagent with 1x  cOmplete mini EDTA-free protease inhibitor cocktail (Roche) with 
a motorized mortar. Tissue lysate was centrifuged at 10,000x g for 5 minutes and the 
supernatant was collected in to a separate microfuge tube. Protein samples were then 
concentrated using a methanol-cholorform extraction as described previously (CITE). 
60μg of total protein lysate was dissolved and boiled at 95°C for 5 minutes in a 1x 
reducing sample buffer (Thermo Scientific). Protein samples were ran on a 4-10% 
polyacrylamide gel at 90V for 20 minutes and then 120V for 60 minutes using Bio-Rad 
Mini-Protean 3 system. Separated proteins were then transferred on to PVDF Immoblion 
P membranes (Millipore) at 100V for two hours. Membranes were blocked with 5% BSA 
with 1x TBST (0.1% tween) for 1 hour. Membranes were then incubated with the 
indicated primary antibody (Table) overnight with shaking at 4°C. The primary antibody 
was removed and the membranes were rinsed three times with 1x TBST (0.1% tween). 
Membranes were then incubated with 1:5000 goat anti-rabbit HRP secondary antibody 
(Santa Cruz) in 5% BSA with 1x TBST (0.1% tween) for two hours with shaking at room 
temperature. Membranes were then rinsed with 1x TBST (0.1% tween) three times and 
then developed using Super Signal West Pico Chemiluminescent substrate (Thermo 
Scientific). Blots were visualized using the Bio-Rad Chemi-doc stations. Densitometry 
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analysis was performed using the Image Lab software (Bio-Rad). Membranes were then 
stripped using a mild stripping buffer (Abcam) and re-blotted with another primary 
antibody. 
Statistics 
Expression of miRNAs and mRNAs in the ovarian hormone deprivation paradigm 
were analyzed by two-way ANOVA with age and treatment as factors. A significant 
interaction between age and treatment was followed by a Tukey’s post hoc test to 
determine statistically significant differences (p<0.05) between groups. A separate 
Tukey’s post-hoc test was performed within groups that showed a statistically significant 
main effect of age and/or treatment. One-way ANOVA with treatment as the main factor, 
followed by Tukey’s posthoc test, was used to determine significant differences of E2, 
DPN, and PPT. All data are presented as mean ± SEM. Statistical significance was noted 
when p<0.05. 
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Table 2. Raw values from miRNA microarray 
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Table 3. DHipp 2-way ANOVA analysis 
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Table 4. PVN 2-way ANOVA analysis 
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Table 5. CeA 2-way ANOVA analysis 
 
  
129 
 
REFERENCE LIST 
 
1. Arias E (2014) United States life tables, 2010. National vital statistics reports : from the 
Centers for Disease Control and Prevention, National Center for Health Statistics, National 
Vital Statistics System 63: 1-63. 
2. Bagger YZ, Tanko LB, Alexandersen P, Qin G, Christiansen C (2005) Early postmenopausal 
hormone therapy may prevent cognitive impairment later in life. Menopause 12: 12-17. 
3. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, et al. (2009) Benefits and 
risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J 
Epidemiol 170: 12-23. 
4. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, et al. (2002) Hormone 
replacement therapy and incidence of Alzheimer disease in older women: the Cache County 
Study. Jama 288: 2123-2129. 
5. Goveas JS, Espeland MA, Hogan P, Dotson V, Tarima S, et al. (2011) Depressive symptoms, 
brain volumes and subclinical cerebrovascular disease in postmenopausal women: the 
Women's Health Initiative MRI Study. J Affect Disord 132: 275-284. 
6. Goveas JS, Espeland MA, Hogan PE, Tindle HA, Shih RA, et al. (2014) Depressive 
Symptoms and Longitudinal Changes in Cognition: Women's Health Initiative Study of 
Cognitive Aging. J Geriatr Psychiatry Neurol 27: 94-102. 
7. Goveas JS, Espeland MA, Woods NF, Wassertheil-Smoller S, Kotchen JM (2011) Depressive 
symptoms and incidence of mild cognitive impairment and probable dementia in elderly 
women: the Women's Health Initiative Memory Study. J Am Geriatr Soc 59: 57-66. 
8. Holsen LM, Spaeth SB, Lee JH, Ogden LA, Klibanski A, et al. (2011) Stress response 
circuitry hypoactivation related to hormonal dysfunction in women with major depression. J 
Affect Disord 131: 379-387. 
9. Jacobs EG, Holsen LM, Lancaster K, Makris N, Whitfield-Gabrieli S, et al. (2015) 17beta-
estradiol differentially regulates stress circuitry activity in healthy and depressed women. 
Neuropsychopharmacology 40: 566-576. 
130 
 
 
 
10. Goldstein JM, Jerram M, Poldrack R, Ahern T, Kennedy DN, et al. (2005) Hormonal cycle 
modulates arousal circuitry in women using functional magnetic resonance imaging. J 
Neurosci 25: 9309-9316. 
11. Komesaroff PA, Esler MD, Sudhir K (1999) Estrogen supplementation attenuates 
glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J 
Clin Endocrinol Metab 84: 606-610. 
12. Zhang QG, Raz L, Wang R, Han D, De Sevilla L, et al. (2009) Estrogen attenuates ischemic 
oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase 
activation. J Neurosci 29: 13823-13836. 
13. Han X, Aenlle KK, Bean LA, Rani A, Semple-Rowland SL, et al. (2013) Role of estrogen 
receptor alpha and beta in preserving hippocampal function during aging. J Neurosci 33: 
2671-2683. 
14. Wang JM, Hou X, Adeosun S, Hill R, Henry S, et al. (2012) A dominant negative ERbeta 
splice variant determines the effectiveness of early or late estrogen therapy after ovariectomy 
in rats. PLoS One 7: e33493. 
15. Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, et al. (2006) A 20-
week randomized controlled trial of estradiol replacement therapy for women aged 70 years 
and older: effect on mood, cognition and quality of life. Neurobiol Aging 27: 141-149. 
16. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, et al. (2013) 
Menopausal hormone therapy and health outcomes during the intervention and extended 
poststopping phases of the Women's Health Initiative randomized trials. Jama 310: 1353-
1368. 
17. Wharton W, Gleason CE, Miller VM, Asthana S (2013) Rationale and design of the Kronos 
Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study 
(KEEPS Cog). Brain Res 1514: 12-17. 
18. Smith CC, Vedder LC, Nelson AR, Bredemann TM, McMahon LL (2010) Duration of 
estrogen deprivation, not chronological age, prevents estrogen's ability to enhance 
hippocampal synaptic physiology. Proc Natl Acad Sci U S A 107: 19543-19548. 
19. Williams TJ, Mitterling KL, Thompson LI, Torres-Reveron A, Waters EM, et al. (2011) Age- 
and hormone-regulation of opioid peptides and synaptic proteins in the rat dorsal 
hippocampal formation. Brain Res 1379: 71-85. 
20. Mizuno T, Chou MY, Inouye M (1984) A unique mechanism regulating gene expression: 
translational inhibition by a complementary RNA transcript (micRNA). Proceedings of the 
National Academy of Sciences of the United States of America 81: 1966-1970. 
131 
 
 
 
21. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell 75: 843-854. 
22. Wightman B, Ha I, Ruvkun G (1993) Posttranscriptional regulation of the heterochronic gene 
lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855-862. 
23. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific 
genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-
811. 
24. Parrish S, Fleenor J, Xu S, Mello C, Fire A (2000) Functional anatomy of a dsRNA trigger: 
differential requirement for the two trigger strands in RNA interference. Mol Cell 6: 1077-
1087. 
25. Montgomery MK, Xu S, Fire A (1998) RNA as a target of double-stranded RNA-mediated 
genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A 95: 15502-15507. 
26. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-
nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-
498. 
27. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T (2001) Identification of novel genes 
coding for small expressed RNAs. Science 294: 853-858. 
28. Lau NC, Lim LP, Weinstein EG, Bartel DP (2001) An abundant class of tiny RNAs with 
probable regulatory roles in Caenorhabditis elegans. Science 294: 858-862. 
29. Lee RC, Ambros V (2001) An extensive class of small RNAs in Caenorhabditis elegans. 
Science 294: 862-864. 
30. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: tools for microRNA 
genomics. Nucleic Acids Res 36: D154-158. 
31. Lee Y, Kim M, Han J, Yeom KH, Lee S, et al. (2004) MicroRNA genes are transcribed by 
RNA polymerase II. Embo J 23: 4051-4060. 
32. Morlando M, Ballarino M, Gromak N, Pagano F, Bozzoni I, et al. (2008) Primary microRNA 
transcripts are processed co-transcriptionally. Nat Struct Mol Biol 15: 902-909. 
33. Ruby JG, Jan CH, Bartel DP (2007) Intronic microRNA precursors that bypass Drosha 
processing. Nature 448: 83-86. 
34. Kim YK, Kim VN (2007) Processing of intronic microRNAs. Embo J 26: 775-783. 
132 
 
 
 
35. Corcoran DL, Pandit KV, Gordon B, Bhattacharjee A, Kaminski N, et al. (2009) Features of 
mammalian microRNA promoters emerge from polymerase II chromatin 
immunoprecipitation data. PLoS One 4: e5279. 
36. Borchert GM, Lanier W, Davidson BL (2006) RNA polymerase III transcribes human 
microRNAs. Nat Struct Mol Biol 13: 1097-1101. 
37. Cai X, Hagedorn CH, Cullen BR (2004) Human microRNAs are processed from capped, 
polyadenylated transcripts that can also function as mRNAs. Rna 10: 1957-1966. 
38. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, et al. (2008) Chromatin structure analyses 
identify miRNA promoters. Genes Dev 22: 3172-3183. 
39. Fujita S, Iba H (2008) Putative promoter regions of miRNA genes involved in evolutionarily 
conserved regulatory systems among vertebrates. Bioinformatics 24: 303-308. 
40. Saini HK, Griffiths-Jones S, Enright AJ (2007) Genomic analysis of human microRNA 
transcripts. Proc Natl Acad Sci U S A 104: 17719-17724. 
41. Zhou X, Ruan J, Wang G, Zhang W (2007) Characterization and identification of microRNA 
core promoters in four model species. PLoS Comput Biol 3: e37. 
42. Monteys AM, Spengler RM, Wan J, Tecedor L, Lennox KA, et al. (2010) Structure and 
activity of putative intronic miRNA promoters. Rna 16: 495-505. 
43. Lee Y, Jeon K, Lee JT, Kim S, Kim VN (2002) MicroRNA maturation: stepwise processing 
and subcellular localization. Embo J 21: 4663-4670. 
44. Pawlicki JM, Steitz JA (2008) Primary microRNA transcript retention at sites of transcription 
leads to enhanced microRNA production. J Cell Biol 182: 61-76. 
45. Lee Y, Ahn C, Han J, Choi H, Kim J, et al. (2003) The nuclear RNase III Drosha initiates 
microRNA processing. Nature 425: 415-419. 
46. Han J, Lee Y, Yeom KH, Nam JW, Heo I, et al. (2006) Molecular basis for the recognition of 
primary microRNAs by the Drosha-DGCR8 complex. Cell 125: 887-901. 
47. Han J, Pedersen JS, Kwon SC, Belair CD, Kim YK, et al. (2009) Posttranscriptional 
crossregulation between Drosha and DGCR8. Cell 136: 75-84. 
48. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA 
precursors. Science 303: 95-98. 
49. Yi R, Qin Y, Macara IG, Cullen BR (2003) Exportin-5 mediates the nuclear export of pre-
microRNAs and short hairpin RNAs. Genes Dev 17: 3011-3016. 
133 
 
 
 
50. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, et al. (2001) A cellular 
function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal 
RNA. Science 293: 834-838. 
51. Lee YS, Nakahara K, Pham JW, Kim K, He Z, et al. (2004) Distinct roles for Drosophila 
Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 117: 69-81. 
52. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al. (2005) TRBP 
recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 
436: 740-744. 
53. Lee HY, Zhou K, Smith AM, Noland CL, Doudna JA (2013) Differential roles of human 
Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic Acids Res 41: 
6568-6576. 
54. Lee HY, Doudna JA (2012) TRBP alters human precursor microRNA processing in vitro. 
Rna 18: 2012-2019. 
55. Okamura K, Liu N, Lai EC (2009) Distinct mechanisms for microRNA strand selection by 
Drosophila Argonautes. Mol Cell 36: 431-444. 
56. Yang JS, Phillips MD, Betel D, Mu P, Ventura A, et al. (2011) Widespread regulatory 
activity of vertebrate microRNA* species. Rna 17: 312-326. 
57. Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT, et al. (2008) The regulatory activity 
of microRNA* species has substantial influence on microRNA and 3' UTR evolution. Nat 
Struct Mol Biol 15: 354-363. 
58. Guo L, Lu Z (2010) The fate of miRNA* strand through evolutionary analysis: implication 
for degradation as merely carrier strand or potential regulatory molecule? PLoS One 5: 
e11387. 
59. Iwasaki S, Kobayashi M, Yoda M, Sakaguchi Y, Katsuma S, et al. (2010) Hsc70/Hsp90 
chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes. Mol 
Cell 39: 292-299. 
60. Yoda M, Kawamata T, Paroo Z, Ye X, Iwasaki S, et al. (2010) ATP-dependent human RISC 
assembly pathways. Nat Struct Mol Biol 17: 17-23. 
61. Wang WX, Wilfred BR, Hu Y, Stromberg AJ, Nelson PT (2010) Anti-Argonaute RIP-Chip 
shows that miRNA transfections alter global patterns of mRNA recruitment to 
microribonucleoprotein complexes. Rna 16: 394-404. 
134 
 
 
 
62. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, et al. (2004) Human 
Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell 15: 185-
197. 
63. Maurin T, Cazalla D, Yang S, Jr., Bortolamiol-Becet D, Lai EC (2012) RNase III-
independent microRNA biogenesis in mammalian cells. Rna 18: 2166-2173. 
64. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on 
protein output. Nature 455: 64-71. 
65. Bethune J, Artus-Revel CG, Filipowicz W (2012) Kinetic analysis reveals successive steps 
leading to miRNA-mediated silencing in mammalian cells. EMBO Rep 13: 716-723. 
66. Jannot G, Bajan S, Giguere NJ, Bouasker S, Banville IH, et al. (2011) The ribosomal protein 
RACK1 is required for microRNA function in both C. elegans and humans. EMBO Rep 12: 
581-586. 
67. Ricci EP, Limousin T, Soto-Rifo R, Rubilar PS, Decimo D, et al. (2013) miRNA repression 
of translation in vitro takes place during 43S ribosomal scanning. Nucleic Acids Res 41: 586-
598. 
68. Chendrimada TP, Finn KJ, Ji X, Baillat D, Gregory RI, et al. (2007) MicroRNA silencing 
through RISC recruitment of eIF6. Nature 447: 823-828. 
69. Nishihara T, Zekri L, Braun JE, Izaurralde E (2013) miRISC recruits decapping factors to 
miRNA targets to enhance their degradation. Nucleic Acids Res 41: 8692-8705. 
70. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, et al. (2011) MicroRNAs can 
generate thresholds in target gene expression. Nat Genet 43: 854-859. 
71. Li X, Cassidy JJ, Reinke CA, Fischboeck S, Carthew RW (2009) A microRNA imparts 
robustness against environmental fluctuation during development. Cell 137: 273-282. 
72. Kozomara A, Hunt S, Ninova M, Griffiths-Jones S, Ronshaugen M (2014) Target repression 
induced by endogenous microRNAs: large differences, small effects. PLoS One 9: e104286. 
73. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, et al. (2004) Expression 
profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with 
possible roles in murine and human neuronal differentiation. Genome Biol 5: R13. 
74. Hua YJ, Tang ZY, Tu K, Zhu L, Li YX, et al. (2009) Identification and target prediction of 
miRNAs specifically expressed in rat neural tissue. BMC Genomics 10: 214. 
75. Bak M, Silahtaroglu A, Moller M, Christensen M, Rath MF, et al. (2008) MicroRNA 
expression in the adult mouse central nervous system. Rna 14: 432-444. 
135 
 
 
 
76. Hu HY, Guo S, Xi J, Yan Z, Fu N, et al. (2011) MicroRNA expression and regulation in 
human, chimpanzee, and macaque brains. PLoS Genet 7: e1002327. 
77. Hohjoh H, Fukushima T (2007) Expression profile analysis of microRNA (miRNA) in mouse 
central nervous system using a new miRNA detection system that examines hybridization 
signals at every step of washing. Gene 391: 39-44. 
78. Olsen L, Klausen M, Helboe L, Nielsen FC, Werge T (2009) MicroRNAs show mutually 
exclusive expression patterns in the brain of adult male rats. PLoS One 4: e7225. 
79. Juhila J, Sipila T, Icay K, Nicorici D, Ellonen P, et al. (2011) MicroRNA expression profiling 
reveals miRNA families regulating specific biological pathways in mouse frontal cortex and 
hippocampus. PLoS One 6: e21495. 
80. Parsons MJ, Grimm CH, Paya-Cano JL, Sugden K, Nietfeld W, et al. (2008) Using 
hippocampal microRNA expression differences between mouse inbred strains to characterise 
miRNA function. Mamm Genome 19: 552-560. 
81. Amar L, Benoit C, Beaumont G, Vacher CM, Crepin D, et al. (2012) MicroRNA expression 
profiling of hypothalamic arcuate and paraventricular nuclei from single rats using Illumina 
sequencing technology. J Neurosci Methods 209: 134-143. 
82. Herzer S, Silahtaroglu A, Meister B (2012) Locked nucleic acid-based in situ hybridisation 
reveals miR-7a as a hypothalamus-enriched microRNA with a distinct expression pattern. J 
Neuroendocrinol 24: 1492-1504. 
83. Kucherenko MM, Barth J, Fiala A, Shcherbata HR (2012) Steroid-induced microRNA let-7 
acts as a spatio-temporal code for neuronal cell fate in the developing Drosophila brain. 
Embo J 31: 4511-4523. 
84. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, et al. (2005) MicroRNAs 
regulate brain morphogenesis in zebrafish. Science 308: 833-838. 
85. Babiarz JE, Hsu R, Melton C, Thomas M, Ullian EM, et al. (2011) A role for noncanonical 
microRNAs in the mammalian brain revealed by phenotypic differences in Dgcr8 versus 
Dicer1 knockouts and small RNA sequencing. Rna 17: 1489-1501. 
86. Miska EA, Alvarez-Saavedra E, Townsend M, Yoshii A, Sestan N, et al. (2004) Microarray 
analysis of microRNA expression in the developing mammalian brain. Genome Biol 5: R68. 
87. Manakov SA, Grant SG, Enright AJ (2009) Reciprocal regulation of microRNA and mRNA 
profiles in neuronal development and synapse formation. BMC Genomics 10: 419. 
136 
 
 
 
88. Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH, et al. (2007) MicroRNAs 
show a wide diversity of expression profiles in the developing and mature central nervous 
system. Genome Biol 8: R173. 
89. Somel M, Liu X, Tang L, Yan Z, Hu H, et al. (2011) MicroRNA-driven developmental 
remodeling in the brain distinguishes humans from other primates. PLoS Biol 9: e1001214. 
90. Smith B, Treadwell J, Zhang D, Ly D, McKinnell I, et al. (2010) Large-scale expression 
analysis reveals distinct microRNA profiles at different stages of human neurodevelopment. 
PLoS One 5: e11109. 
91. Conaco C, Otto S, Han JJ, Mandel G (2006) Reciprocal actions of REST and a microRNA 
promote neuronal identity. Proc Natl Acad Sci U S A 103: 2422-2427. 
92. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, et al. (2011) MicroRNA-mediated 
conversion of human fibroblasts to neurons. Nature 476: 228-231. 
93. Jovicic A, Roshan R, Moisoi N, Pradervand S, Moser R, et al. (2013) Comprehensive 
expression analyses of neural cell-type-specific miRNAs identify new determinants of the 
specification and maintenance of neuronal phenotypes. J Neurosci 33: 5127-5137. 
94. He M, Liu Y, Wang X, Zhang MQ, Hannon GJ, et al. (2012) Cell-type-based analysis of 
microRNA profiles in the mouse brain. Neuron 73: 35-48. 
95. Kye MJ, Liu T, Levy SF, Xu NL, Groves BB, et al. (2007) Somatodendritic microRNAs 
identified by laser capture and multiplex RT-PCR. Rna 13: 1224-1234. 
96. Lugli G, Torvik VI, Larson J, Smalheiser NR (2008) Expression of microRNAs and their 
precursors in synaptic fractions of adult mouse forebrain. J Neurochem 106: 650-661. 
97. Barbato C, Ciotti MT, Serafino A, Calissano P, Cogoni C (2007) Dicer expression and 
localization in post-mitotic neurons. Brain Res 1175: 17-27. 
98. Cougot N, Bhattacharyya SN, Tapia-Arancibia L, Bordonne R, Filipowicz W, et al. (2008) 
Dendrites of mammalian neurons contain specialized P-body-like structures that respond to 
neuronal activation. J Neurosci 28: 13793-13804. 
99. Nelson PT, Hatzigeorgiou AG, Mourelatos Z (2004) miRNP:mRNA association in 
polyribosomes in a human neuronal cell line. Rna 10: 387-394. 
100. Kim J, Krichevsky A, Grad Y, Hayes GD, Kosik KS, et al. (2004) Identification of many 
microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U 
S A 101: 360-365. 
137 
 
 
 
101. Krol J, Busskamp V, Markiewicz I, Stadler MB, Ribi S, et al. (2010) Characterizing light-
regulated retinal microRNAs reveals rapid turnover as a common property of neuronal 
microRNAs. Cell 141: 618-631. 
102. Eacker SM, Keuss MJ, Berezikov E, Dawson VL, Dawson TM (2011) Neuronal activity 
regulates hippocampal miRNA expression. PLoS One 6: e25068. 
103. Konopka W, Kiryk A, Novak M, Herwerth M, Parkitna JR, et al. (2010) MicroRNA loss 
enhances learning and memory in mice. J Neurosci 30: 14835-14842. 
104. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, et al. (2010) microRNA-
132 regulates dendritic growth and arborization of newborn neurons in the adult 
hippocampus. Proc Natl Acad Sci U S A 107: 20382-20387. 
105. Lambert TJ, Storm DR, Sullivan JM (2010) MicroRNA132 modulates short-term synaptic 
plasticity but not basal release probability in hippocampal neurons. PLoS One 5: e15182. 
106. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, et al. (2006) A brain-specific 
microRNA regulates dendritic spine development. Nature 439: 283-289. 
107. Gao J, Wang WY, Mao YW, Graff J, Guan JS, et al. (2010) A novel pathway regulates 
memory and plasticity via SIRT1 and miR-134. Nature 466: 1105-1109. 
108. Ibanez-Ventoso C, Yang M, Guo S, Robins H, Padgett RW, et al. (2006) Modulated 
microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell 5: 235-
246. 
109. Kato M, Chen X, Inukai S, Zhao H, Slack FJ (2011) Age-associated changes in expression of 
small, noncoding RNAs, including microRNAs, in C. elegans. Rna 17: 1804-1820. 
110. de Lencastre A, Pincus Z, Zhou K, Kato M, Lee SS, et al. (2010) MicroRNAs both promote 
and antagonize longevity in C. elegans. Curr Biol 20: 2159-2168. 
111. Inukai S, de Lencastre A, Turner M, Slack F (2012) Novel microRNAs differentially 
expressed during aging in the mouse brain. PLoS One 7: e40028. 
112. Li N, Bates DJ, An J, Terry DA, Wang E (2011) Up-regulation of key microRNAs, and 
inverse down-regulation of their predicted oxidative phosphorylation target genes, during 
aging in mouse brain. Neurobiol Aging 32: 944-955. 
113. Li X, Khanna A, Li N, Wang E (2011) Circulatory miR34a as an RNAbased, noninvasive 
biomarker for brain aging. Aging (Albany NY) 3: 985-1002. 
138 
 
 
 
114. Somel M, Guo S, Fu N, Yan Z, Hu HY, et al. (2010) MicroRNA, mRNA, and protein 
expression link development and aging in human and macaque brain. Genome Res 20: 1207-
1218. 
115. Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, et al. (2010) 
microRNA expression patterns reveal differential expression of target genes with age. PLoS 
One 5: e10724. 
116. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, et al. (2009) Estradiol-
regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 37: 
4850-4861. 
117. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, et al. (2009) Estradiol 
downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 
breast cancer cells. Nucleic Acids Res 37: 2584-2595. 
118. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, et al. (2009) The estrogen 
receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. 
Proc Natl Acad Sci U S A 106: 15732-15737. 
119. Masuda M, Miki Y, Hata S, Takagi K, Sakurai M, et al. (2012) An induction of microRNA, 
miR-7 through estrogen treatment in breast carcinoma. J Transl Med 10 Suppl 1: S2. 
120. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, et al. (2009) Widespread 
estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res 
69: 8332-8340. 
121. Paris O, Ferraro L, Grober OM, Ravo M, De Filippo MR, et al. (2012) Direct regulation of 
microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast 
cancer. Oncogene 31: 4196-4206. 
122. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, et al. (2009) MicroRNA 
signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in 
breast cancer. Breast Cancer Res 11: R27. 
123. Persengiev S, Kondova I, Otting N, Koeppen AH, Bontrop RE (2011) Genome-wide analysis 
of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar 
ataxia pathogenesis. Neurobiol Aging 32: 2316 e2317-2327. 
124. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) Identification of mammalian 
microRNA host genes and transcription units. Genome Res 14: 1902-1910. 
139 
 
 
 
125. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, et al. (2001) Dicer functions in 
RNA interference and in synthesis of small RNA involved in developmental timing in C. 
elegans. Genes Dev 15: 2654-2659. 
126. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly 
act to decrease target mRNA levels. Nature 466: 835-840. 
127. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, et al. (2008) Widespread 
changes in protein synthesis induced by microRNAs. Nature 455: 58-63. 
128. Kuokkanen S, Chen B, Ojalvo L, Benard L, Santoro N, et al. (2010) Genomic profiling of 
microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in 
human endometrium. Biol Reprod 82: 791-801. 
129. Nothnick WB, Healy C, Hong X (2010) Steroidal regulation of uterine miRNAs is associated 
with modulation of the miRNA biogenesis components Exportin-5 and Dicer1. Endocrine 37: 
265-273. 
130. Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, et al. (2009) Maturation of microRNA is 
hormonally regulated by a nuclear receptor. Mol Cell 36: 340-347. 
131. Fernandez SM, Lewis MC, Pechenino AS, Harburger LL, Orr PT, et al. (2008) Estradiol-
induced enhancement of object memory consolidation involves hippocampal extracellular 
signal-regulated kinase activation and membrane-bound estrogen receptors. J Neurosci 28: 
8660-8667. 
132. Liu F, Day M, Muniz LC, Bitran D, Arias R, et al. (2008) Activation of estrogen receptor-
beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci 11: 334-
343. 
133. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, et al. (2004) Conjugated equine 
estrogens and incidence of probable dementia and mild cognitive impairment in 
postmenopausal women: Women's Health Initiative Memory Study. Jama 291: 2947-2958. 
134. Choi SD, Steinberg EM, Lee HH, Naftolin F (2011) The Timing Hypothesis remains a valid 
explanation of differential cardioprotective effects of menopausal hormone treatment. 
Menopause 18: 230-236. 
135. Hamilton RT, Rettberg JR, Mao Z, To J, Zhao L, et al. (2011) Hippocampal responsiveness 
to 17beta-estradiol and equol after long-term ovariectomy: implication for a therapeutic 
window of opportunity. Brain Res 1379: 11-22. 
140 
 
 
 
136. Morrison JH, Brinton RD, Schmidt PJ, Gore AC (2006) Estrogen, menopause, and the aging 
brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 26: 10332-
10348. 
137. Hibberd C, Yau JL, Seckl JR (2000) Glucocorticoids and the ageing hippocampus. J Anat 
197 Pt 4: 553-562. 
138. Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, et al. (2008) Uncovering the 
mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol 29: 219-
237. 
139. Belujon P, Grace AA (2011) Hippocampus, amygdala, and stress: interacting systems that 
affect susceptibility to addiction. Ann N Y Acad Sci 1216: 114-121. 
140. Fanselow MS, Dong HW (2010) Are the dorsal and ventral hippocampus functionally distinct 
structures? Neuron 65: 7-19. 
141. Dong HW, Swanson LW, Chen L, Fanselow MS, Toga AW (2009) Genomic-anatomic 
evidence for distinct functional domains in hippocampal field CA1. Proc Natl Acad Sci U S 
A 106: 11794-11799. 
142. Thompson CL, Pathak SD, Jeromin A, Ng LL, MacPherson CR, et al. (2008) Genomic 
anatomy of the hippocampus. Neuron 60: 1010-1021. 
143. Cohen JE, Lee PR, Chen S, Li W, Fields RD (2011) MicroRNA regulation of homeostatic 
synaptic plasticity. Proc Natl Acad Sci U S A 108: 11650-11655. 
144. Schaefer A, O'Carroll D, Tan CL, Hillman D, Sugimori M, et al. (2007) Cerebellar 
neurodegeneration in the absence of microRNAs. J Exp Med 204: 1553-1558. 
145. Wu D, Raafat A, Pak E, Clemens S, Murashov AK Dicer-microRNA pathway is critical for 
peripheral nerve regeneration and functional recovery in vivo and regenerative axonogenesis 
in vitro. Exp Neurol 233: 555-565. 
146. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010) miR-16 
targets the serotonin transporter: a new facet for adaptive responses to antidepressants. 
Science 329: 1537-1541. 
147. Haramati S, Navon I, Issler O, Ezra-Nevo G, Gil S, et al. (2011) MicroRNA as repressors of 
stress-induced anxiety: the case of amygdalar miR-34. J Neurosci 31: 14191-14203. 
148. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, et al. (2012) MicroRNA-132 dysregulation in 
schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl 
Acad Sci U S A 109: 3125-3130. 
141 
 
 
 
149. Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM (2011) Altered microRNA 
expression profiles in postmortem brain samples from individuals with schizophrenia and 
bipolar disorder. Biol Psychiatry 69: 188-193. 
150. Packer AN, Xing Y, Harper SQ, Jones L, Davidson BL (2008) The bifunctional microRNA 
miR-9/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease. J 
Neurosci 28: 14341-14346. 
151. Sethi P, Lukiw WJ (2009) Micro-RNA abundance and stability in human brain: specific 
alterations in Alzheimer's disease temporal lobe neocortex. Neurosci Lett 459: 100-104. 
152. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Res 19: 92-105. 
153. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, et al. (2007) MicroRNA 
targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 27: 91-105. 
154. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, 
indicates that thousands of human genes are microRNA targets. Cell 120: 15-20. 
155. Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: 
targets and expression. Nucleic Acids Res 36: D149-153. 
156. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, et al. (2012) DIANA 
miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic 
Acids Res 40: W498-504. 
157. Libert S, Pointer K, Bell EL, Das A, Cohen DE, et al. (2011) SIRT1 activates MAO-A in the 
brain to mediate anxiety and exploratory drive. Cell 147: 1459-1472. 
158. Inukai S, de Lencastre A, Turner M, Slack F (2012) Novel microRNAs differentially 
expressed during aging in the mouse brain. PloS one 7. 
159. Kumar A, Gibbs J, Beilina A, Dillman A, Kumaran R, et al. (2012) Age-associated changes 
in gene expression in human brain and isolated neurons. Neurobiology of aging. 
160. Lee C, Weindruch R, Prolla T (2000) Gene-expression profile of the ageing brain in mice. 
Nature genetics 25: 294-297. 
161. Li N, Bates D, An J, Terry D, Wang E (2011) Up-regulation of key microRNAs, and inverse 
down-regulation of their predicted oxidative phosphorylation target genes, during aging in 
mouse brain. Neurobiology of aging 32: 944-955. 
162. Lu T, Pan Y, Kao S-Y, Li C, Kohane I, et al. (2004) Gene regulation and DNA damage in the 
ageing human brain. Nature 429: 883-891. 
142 
 
 
 
163. Somel M, Guo S, Fu N, Yan Z, Hu H, et al. (2010) MicroRNA, mRNA, and protein 
expression link development and aging in human and macaque brain. Genome research 20: 
1207-1218. 
164. Wu D, Gore AC (2010) Changes in androgen receptor, estrogen receptor alpha, and sexual 
behavior with aging and testosterone in male rats. Horm Behav 58: 306-316. 
165. Moore RL, Dai Y, Faller DV (2012) Sirtuin 1 (SIRT1) and steroid hormone receptor activity 
in cancer. J Endocrinol 213: 37-48. 
166. Osterlund M, Kuiper GG, Gustafsson JA, Hurd YL (1998) Differential distribution and 
regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res 
Mol Brain Res 54: 175-180. 
167. Shughrue PJ, Merchenthaler I (2001) Distribution of estrogen receptor beta immunoreactivity 
in the rat central nervous system. J Comp Neurol 436: 64-81. 
168. Shima N, Yamaguchi Y, Yuri K (2003) Distribution of estrogen receptor beta mRNA-
containing cells in ovariectomized and estrogen-treated female rat brain. Anat Sci Int 78: 85-
97. 
169. Walker DM, Juenger TE, Gore AC (2009) Developmental profiles of neuroendocrine gene 
expression in the preoptic area of male rats. Endocrinology 150: 2308-2316. 
170. Lin SJ, Defossez PA, Guarente L (2000) Requirement of NAD and SIR2 for life-span 
extension by calorie restriction in Saccharomyces cerevisiae. Science 289: 2126-2128. 
171. Rogina B, Helfand SL (2004) Sir2 mediates longevity in the fly through a pathway related to 
calorie restriction. Proc Natl Acad Sci U S A 101: 15998-16003. 
172. Longo VD, Kennedy BK (2006) Sirtuins in aging and age-related disease. Cell 126: 257-268. 
173. Schonrock N, Humphreys DT, Preiss T, Gotz J (2012) Target gene repression mediated by 
miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-beta. J Mol 
Neurosci 46: 324-335. 
174. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W (2006) Relief of 
microRNA-mediated translational repression in human cells subjected to stress. Cell 125: 
1111-1124. 
175. Yang LC, Zhang QG, Zhou CF, Yang F, Zhang YD, et al. Extranuclear estrogen receptors 
mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS One 5: e9851. 
143 
 
 
 
176. Colenda CC, Legault C, Rapp SR, DeBon MW, Hogan P, et al. (2010) Psychiatric disorders 
and cognitive dysfunction among older, postmenopausal women: results from the Women's 
Health Initiative Memory Study. Am J Geriatr Psychiatry 18: 177-186. 
177. Ferrini M, Lima A, De Nicola AF (1995) Estradiol abolishes autologous down regulation of 
glucocorticoid receptors in brain. Life Sci 57: 2403-2412. 
178. Yao J, Hamilton RT, Cadenas E, Brinton RD (2010) Decline in mitochondrial bioenergetics 
and shift to ketogenic profile in brain during reproductive senescence. Biochim Biophys Acta 
1800: 1121-1126. 
179. Espeland MA, Brunner RL, Hogan PE, Rapp SR, Coker LH, et al. (2010) Long-term effects 
of conjugated equine estrogen therapies on domain-specific cognitive function: results from 
the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc 58: 1263-
1271. 
180. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, et al. (2004) Conjugated 
equine estrogens and global cognitive function in postmenopausal women: Women's Health 
Initiative Memory Study. Jama 291: 2959-2968. 
181. Heo I, Joo C, Cho J, Ha M, Han J, et al. (2008) Lin28 mediates the terminal uridylation of let-
7 precursor MicroRNA. Mol Cell 32: 276-284. 
182. De N, Young L, Lau PW, Meisner NC, Morrissey DV, et al. (2013) Highly complementary 
target RNAs promote release of guide RNAs from human Argonaute2. Mol Cell 50: 344-355. 
183. Gantier MP, McCoy CE, Rusinova I, Saulep D, Wang D, et al. (2011) Analysis of microRNA 
turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res 39: 5692-5703. 
184. Burroughs AM, Ando Y, de Hoon MJ, Tomaru Y, Nishibu T, et al. (2010) A comprehensive 
survey of 3' animal miRNA modification events and a possible role for 3' adenylation in 
modulating miRNA targeting effectiveness. Genome Res 20: 1398-1410. 
185. Wyman SK, Knouf EC, Parkin RK, Fritz BR, Lin DW, et al. (2011) Post-transcriptional 
generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA 
transcriptome complexity. Genome Res 21: 1450-1461. 
186. Chatterjee S, Grosshans H (2009) Active turnover modulates mature microRNA activity in 
Caenorhabditis elegans. Nature 461: 546-549. 
187. Wu D, Raafat A, Pak E, Clemens S, Murashov AK (2012) Dicer-microRNA pathway is 
critical for peripheral nerve regeneration and functional recovery in vivo and regenerative 
axonogenesis in vitro. Exp Neurol 233: 555-565. 
144 
 
 
 
188. Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, et al. (2014) miR-1202 is a primate-
specific and brain-enriched microRNA involved in major depression and antidepressant 
treatment. Nature Medicine 20: 764-768. 
189. Morgan CP, Bale TL (2011) Early prenatal stress epigenetically programs dysmasculinization 
in second-generation offspring via the paternal lineage. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 31: 11748-11755. 
190. Rao YS, Mott NN, Wang Y, Chung WC, Pak TR (2013) MicroRNAs in the aging female 
brain: a putative mechanism for age-specific estrogen effects. Endocrinology 154: 2795-
2806. 
191. Toufexis DJ, Myers KM, Bowser ME, Davis M (2007) Estrogen disrupts the inhibition of 
fear in female rats, possibly through the antagonistic effects of estrogen receptor alpha 
(ERalpha) and ERbeta. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 27: 9729-9735. 
192. Miller WJ, Suzuki S, Miller LK, Handa R, Uht RM (2004) Estrogen receptor (ER)beta 
isoforms rather than ERalpha regulate corticotropin-releasing hormone promoter activity 
through an alternate pathway. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 24: 10628-10635. 
193. Ferraro L, Ravo M, Nassa G, Tarallo R, De Filippo MR, et al. (2012) Effects of oestrogen on 
microRNA expression in hormone-responsive breast cancer cells. Hormones & cancer 3: 65-
78. 
194. Vesely C, Tauber S, Sedlazeck FJ, Tajaddod M, von Haeseler A, et al. (2014) ADAR2 
induces reproducible changes in sequence and abundance of mature microRNAs in the mouse 
brain. Nucleic acids research 42: 12155-12168. 
195. Abe M, Naqvi A, Hendriks GJ, Feltzin V, Zhu Y, et al. (2014) Impact of age-associated 
increase in 2'-O-methylation of miRNAs on aging and neurodegeneration in Drosophila. 
Genes & Development 28: 44-57. 
196. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, et al. (2013) EGFR modulates 
microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 
497: 383-387. 
197. Chakraborty TR, Hof PR, Ng L, Gore AC (2003) Stereologic analysis of estrogen receptor 
alpha (ER alpha) expression in rat hypothalamus and its regulation by aging and estrogen. J 
Comp Neurol 466: 409-421. 
198. Chakraborty TR, Ng L, Gore AC (2003) Age-related changes in estrogen receptor beta in rat 
hypothalamus: a quantitative analysis. Endocrinology 144: 4164-4171. 
145 
 
 
 
199. Kermath BA, Riha PD, Woller MJ, Wolfe A, Gore AC (2014) Hypothalamic molecular 
changes underlying natural reproductive senescence in the female rat. Endocrinology 155: 
3597-3609. 
200. Mott NN, Pak TR (2012) Characterisation of human oestrogen receptor beta (ERbeta) splice 
variants in neuronal cells. J Neuroendocrinol 24: 1311-1321. 
201. Pak TR, Chung WC, Roberts JL, Handa RJ (2006) Ligand-independent effects of estrogen 
receptor beta on mouse gonadotropin-releasing hormone promoter activity. Endocrinology 
147: 1924-1931. 
202. Mott NN, Pinceti E, Rao YS, Przybycien-Szymanska MM, Prins SA, et al. (2014) Age-
dependent Effects of 17beta-estradiol on the dynamics of estrogen receptor beta (ERbeta) 
protein-protein interactions in the ventral hippocampus. Mol Cell Proteomics 13: 760-779. 
203. Oyola MG, Portillo W, Reyna A, Foradori CD, Kudwa A, et al. (2012) Anxiolytic effects and 
neuroanatomical targets of estrogen receptor-beta (ERbeta) activation by a selective ERbeta 
agonist in female mice. Endocrinology 153: 837-846. 
204. Weiser MJ, Wu TJ, Handa RJ (2009) Estrogen receptor-beta agonist diarylpropionitrile: 
biological activities of R- and S-enantiomers on behavior and hormonal response to stress. 
Endocrinology 150: 1817-1825. 
205. Kasckow J, Mulchahey JJ, Aguilera G, Pisarska M, Nikodemova M, et al. (2003) 
Corticotropin-releasing hormone (CRH) expression and protein kinase A mediated CRH 
receptor signalling in an immortalized hypothalamic cell line. J Neuroendocrinol 15: 521-
529. 
206. Davis JB, Maher P (1994) Protein kinase C activation inhibits glutamate-induced cytotoxicity 
in a neuronal cell line. Brain Res 652: 169-173. 
207. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, et al. (2012) An unconventional 
role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat 
Neurosci 15: 827-835. 
208. Molotski N, Soen Y (2012) Differential association of microRNAs with polysomes reflects 
distinct strengths of interactions with their mRNA targets. Rna 18: 1612-1623. 
209. Bail S, Swerdel M, Liu H, Jiao X, Goff LA, et al. (2010) Differential regulation of 
microRNA stability. Rna 16: 1032-1039. 
210. Ren G, Xie M, Zhang S, Vinovskis C, Chen X, et al. (2014) Methylation protects microRNAs 
from an AGO1-associated activity that uridylates 5' RNA fragments generated by AGO1 
cleavage. Proc Natl Acad Sci U S A 111: 6365-6370. 
146 
 
 
 
211. Yamaguchi N, Yuri K (2014) Estrogen-dependent changes in estrogen receptor-beta mRNA 
expression in middle-aged female rat brain. Brain Res 1543: 49-57. 
212. Xu XL, Zong R, Li Z, Biswas MH, Fang Z, et al. (2011) FXR1P but not FMRP regulates the 
levels of mammalian brain-specific microRNA-9 and microRNA-124. J Neurosci 31: 13705-
13709. 
213. Orom UA, Nielsen FC, Lund AH (2008) MicroRNA-10a binds the 5'UTR of ribosomal 
protein mRNAs and enhances their translation. Mol Cell 30: 460-471. 
214. Panda AC, Sahu I, Kulkarni SD, Martindale JL, Abdelmohsen K, et al. (2014) miR-196b-
mediated translation regulation of mouse insulin2 via the 5'UTR. PLoS One 9: e101084. 
215. Zhou H, Rigoutsos I (2014) MiR-103a-3p targets the 5' UTR of GPRC5A in pancreatic cells. 
Rna 20: 1431-1439. 
216. Hwang HW, Wentzel EA, Mendell JT (2007) A hexanucleotide element directs microRNA 
nuclear import. Science 315: 97-100. 
217. Redfern AD, Colley SM, Beveridge DJ, Ikeda N, Epis MR, et al. (2013) RNA-induced 
silencing complex (RISC) Proteins PACT, TRBP, and Dicer are SRA binding nuclear 
receptor coregulators. Proc Natl Acad Sci U S A 110: 6536-6541. 
218. Allo M, Agirre E, Bessonov S, Bertucci P, Gomez Acuna L, et al. (2014) Argonaute-1 binds 
transcriptional enhancers and controls constitutive and alternative splicing in human cells. 
Proc Natl Acad Sci U S A 111: 15622-15629. 
219. Zhang Y, Fan M, Zhang X, Huang F, Wu K, et al. (2014) Cellular microRNAs up-regulate 
transcription via interaction with promoter TATA-box motifs. Rna 20: 1878-1889. 
220. Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, et al. (2010) Long noncoding 
RNA as modular scaffold of histone modification complexes. Science 329: 689-693. 
221. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, et al. (2010) Long non-coding RNA 
HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464: 1071-1076. 
222. Tebar M, Ruiz A, Bellido C, Sanchez-Criado JE (1996) Ovary mediates the effects of RU486 
given during proestrus on the diestrous secretion of luteinizing hormone in the rat. Biol 
Reprod 54: 1266-1270. 
223. Schmittgen TD, Jiang J, Liu Q, Yang L (2004) A high-throughput method to monitor the 
expression of microRNA precursors. Nucleic acids research 32: e43. 
224. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. 
147 
 
 
 
225. Maroney PA, Chamnongpol S, Souret F, Nilsen TW (2007) A rapid, quantitative assay for 
direct detection of microRNAs and other small RNAs using splinted ligation. Rna 13: 930-
936. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
148 
 
VITA 
 
The author, Yathindar (Yathi) S. Rao was born in Chicago, IL on February 26th, 1985 to 
Satya and Nagamani Rao. He attended and received a bachelor’s degree in Biology at Loyola 
University Chicago (Chicago, IL) in 2007.  
 In August of 2007, Yathi joined the master’s program of Molecular and Cellular 
Biochemistry at Loyola University Medical Center (Maywood, IL).  Shortly thereafter, he joined 
the laboratory of Dr. Toni R. Pak, where he studied kisspeptin signaling in the hypothalamo-
pituitary-adrenal axis. Yathi published his first paper on his master’s thesis and received his 
master’s degree in 2009. Yathi then joined the PhD program at Loyola and continued to work Dr. 
Pak’s lab studying the regulation of microRNAs in the aging female brain by 17β-estradiol. 
While at Loyola, Yathi received a travel award from the Endocrine Society, represented Loyola in 
the pre-doctoral oral presentation competition at the annual meeting of the Chicago chapter of 
Society for Neuroscience, and the Arthur J. Schmitt Dissertation Fellowship. Yathi married his 
fiancé, Georgina Giffin, in 2010. In October of 2014, Yathi and Georgina welcomed the birth of 
their first child Kailas Oliver Giffin-Rao. 
After completing his Ph.D., Yathi will begin a post-doctoral position in Dr. Mary Jo 
LaDu’s laboratory at the University of Illinois at Chicago (Chicago, IL) where he will study 
apoplioprotein E (APOE) and Alzheimer’s disease.
 
